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Abstract
Skin provides the protective surface for animals and humans and is therefore prone to
physical, chemical, and biological injuries. In all but superficial wounds, the capacity to
repair by regeneration is lost and the mechanisms involved in wound closure are unable
to restore the skin’s original functions. In this context, skin repair is achieved using
surgical techniques including skin grafts, and a range of synthetic or biological
scaffolds. Wounds impact millions of patients every year and represent a serious cause
of morbidity and mortality worldwide. The increase in need for better skin repair, in part
due to issues such as the aging population coupled with chronic conditions has driven
the development of products to enhance therapeutic outcomes, yet current treatment
outcomes are far from ideal and complete replication of the cellular structure and tissue
functional requirements of skin remains a challenge.

General aims: Address the major drawbacks of available skin substitutes and delivery
system platforms. Herein two approaches are proposed, the first one (Chapters 2-3)
involves the development and initial in vitro characterization of a 3D multifunctional
bioprinted platform based on platelet lysate, which could be used to deliver cells and
growth factors to the wound site while providing a supportive network that mimics the
native ECM for skin cells to infiltrate and thrive. This system was designed with the aim
of providing an advanced alternative to current skin grafts and skin substitutes available
for clinical use. The second system proposed (Chapter 4) is based on an electrofluidic
approach for control of bioactive molecule delivery into soft tissue model using threads
and surgical sutures which was designed with the aim of being used in sutures for
surgical wound closure.

I

Methods: (Chapter 2-3) 3D printed HDF-PLGMA bioink were fabricated using a
pneumatic extrusion-based 3D Bioplotter. The epidermal-dermal model was fabricated
by seeding HaCaT on top of 3D printed HDF-PLGMA constructs. The innervated
dermal model was fabricated by seed hNSC H9 neurospheres to the bottom of 3D
printed HDF-PLGMA constructs. (Chapter 4) Commonly employed surgical sutures
were used to create an adequate fluid connection between the electrodes and a tissuelike 3D hydrogel support. The platform consisted of two reservoirs into which the ends
of the thread/suture were immersed. The anode and cathode were placed separately into
each reservoir. The thread/suture was taken from one reservoir to the other through the
gel. When the current was applied, biomolecules loaded onto the thread/suture were
directed into the gel, and the rate of movement of the biomolecules was dependent on
the magnitude of the current.

Results: (Chapter 2) Briefly, the work described in this chapter relates to the
development of a multifunctional bioink consisting of PL and GelMA (PLGMA) and
the biofabrication of a 3D printed dermal-like structure. The data presented shows that
the proposed PLGMA bioink meets essential requirements of printability in terms of
rheological properties and shape fidelity. Moreover, its mechanical properties can be
readily tuned to achieve stiffness that is equivalent to native skin tissue. Biologically
relevant factors were successfully released in a sustainable manner and the
bioavailability of those factors was demonstrated by high cell viability, good cell
attachment, and improved proliferation of printed dermal fibroblasts, as well as by
upregulation of ECM synthesis by dermal fibroblasts. (Chapter 3) Continuing the work
described in chapter 2, chapter 3 relates the fabrication of a more complex skin
equivalent based on the PLGMA platform previously established. Bilayer skin model:
II

The expression of general keratinocyte differentiation markers was used to confirm the
capacity of the platform to promote normal epithelial morphogenesis and differentiation
of keratinocytes. Innervated skin model: The expression of development neuronal
markers, as well as a general neuronal marker, was used to demonstrate that the
proposed platform supported hNSC-H9 neurosphere neurite outgrowth and neuronal
differentiation. Challenges faced in the co-incorporation of HaCaT and hNSC-H9
neurospheres to HDF-PLGMA construct that need to be considered to progress with this
research will also be presented. (Chapter 4) A novel electrofludic system for the
controlled release of bioactive molecules such as small molecules, drugs,
polysaccharides, or proteins via an electric field is described for the first time. In a
proof-of-concept study, the controlled delivery of dexamethasone 21-phosphate
disodium salt (DSP), a clinically relevant anti-inflammatory prodrug, as well as other
molecules were used to demonstrate the feasibility of the proposed system. Despite
being peripherally related to the overall PhD theme; this system could be potentially
integrated in the PLGMA matrix by printing the 3D skin cells-PLGMA on top of the
suture for precise delivery of growth factors and cells to sutured wounds.

Taken together, although it is still at an early stage of development, the bioprinting
platform, as well as the electrofludic systems demonstrated to hold potential as a
foundation for the fabrication of complex and physiologically relevant delivery
platforms for wound management and tissue regeneration.

.
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Introduction
Part of the review presented in this chapter formed the basis of a first author review paper
published to the journal Advanced Functional Materials 1616-301X (2021).
https://doi.org/10.1002/adfm.202105080 by Daikuara, Luciana Y.; Chen, Xifang; Yue,
Zhilian; Skropeta, Danielle; Wood, Fiona M.; Fear, Mark W.; Wallace, Gordon G.
Bioprinting for complex skin constructs fabrication
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1.1

Introduction

This general introductory chapter includes the background information about the skin,
wound healing, current treatments, and the need for advanced alternatives. The 3D
printing and electrofluidic approaches this thesis will be focussing on, as well as the
gaps in the clinic that are driving the investigation will also be introduced in this
chapter. Relevant information will be further discussed in corresponding chapters.
Briefly, following chapters 2-3 will detail the development and initial in vitro
characterisation of a 3D multifunctional bioprinted platform based on platelet lysate.
Chapter 4 will detail the design and proof-of-concept study of the electrofluidic
approach for controlled delivery of bioactive molecule into soft tissue model using
threads/surgical sutures. Lastly, chapter 5 will present the conclusion and future
directions of this research.

1.2

Skin tissue

3

Figure 1.1 Cross-section of the human skin showing its multi-layered structure.
Adapted from [1]

Skin, the largest organ of the human body, is formed by a highly stratified and multilayered structure (Figure 1.1). The skin’s primary role is to protect the internal organs
from the external environment,[2-4] but it also performs a range of regulatory,
perceptive, cosmetic and supplementary functions.[2] The skin is composed of three
main layers: epidermis, dermis, and hypodermis.[5] The outer most layer of the
epithelium, the epidermis, is responsible for the mechanical strength and physical
protection of the skin, preventing moisture loss and pathogen entry.[6] This avascular
layer is composed mainly of keratinocytes, but also contains other cell lines such as
melanocytes and Langerhans cells.[2, 7] Beneath the epidermal layer is the dermis, this
layer provides elasticity and mechanical integrity, besides a vascular plexus to nourish
the integument. It consists of various glycosaminoglycans (GAGs), elastin and collagen,
which compose the extracellular matrix (ECM).[8] Skin appendages, such as hair
follicles, nail, sebaceous, sweat and apocrine glands can also be found in this layer.[9]
The cellular components of the dermal layer include fibroblasts, endothelial cells,
smooth muscle cells and mast cells.[10] Hypodermis, the most inner layer of the skin, is
composed by loose fatty connective tissue.[11] Lipocytes and collagen present on this
layer assist in the regulation of the body temperature and homeostasis.[10]

1.3
1.3.1

Skin components
Fibroblasts

Fibroblasts are a highly heterogeneous and dynamic cell lineage prevalent in the human
dermis, which plays an important role in the healing process by maintaining the physical
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integrity of connective tissue. Fibroblasts are remarkably plastic in nature and are
capable of altering its function, physiology or transitioning into a new cell type such as
myofibroblasts.[12] During the early stages of the healing process, fibroblasts occupy
the provisional matrix composed of fibrin, fibrinogen and fibronectin, and proliferate in
response to cytokines produced by neutrophils and macrophages that have migrated into
the wound tissue. Then, a series of factors such as mechanical tension, cytokines and
TGF-β drive the phenotypic change of fibroblasts to myofibroblasts. Myofibroblasts
exhibit decreased proliferative capacity and increased deposition of the dense, fibrotic
collagen matrix (comprising of collagen I, III, IV, and V) and wound contraction.
During the remodelling phase, myofibroblasts produce decorin, which regulates
collagen fibrillogenesis. Matrix breakdown promotes disassembly of cellular focal
adhesions, the reduced ability of myofibroblasts to adhere to the matrix leads to cellular
apoptosis, with the myofibroblasts apoptosis towards the end of the healing phase, a
collagen-rich, hypocellular scar is formed.[13]

1.3.2

Keratinocytes

Keratinocytes are the main cellular component of the outermost layer of the skin, and
function as a barrier against the outer environment.[13] Keratinocytes are involved in
alterations in the cell-matrix adhesions and cell-cell junction that are crucial for wound
closure and reepithelization.[14] Moreover, keratinocytes secrete ECM, growth factors
and matrix metalloproteinases, which are key regulators of multiple aspects of tissue
repair. Matrix metalloproteinases (MMPs) that are mostly deposited by keratinocytes
are: MMP-1, MMP-7, MMP-9, and MMP-10. MMP-1 expression rises rapidly in
response to injury and peaks in migrating basal keratinocytes at the wound margin at
day 1 followed by a gradual decrease, until being undetectable when reepithelization is
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completed.[13] Activation signals of several driving growth factors such as hepatocyte
growth factor (HGF), fibroblast growth factor (FGF) and epidermal growth factor
(EGF) by keratinocytes are also needed to induce reepithelialisation.[14] The
production of transforming growth factor (TGF- β1 and - β3) by human keratinocytes is
required to assist preventing excessive scar formation.[13]

1.3.3

Extracellular matrix

The extracellular matrix is a highly dynamic microenvironment that comprises the
noncellular component present in tissues. The composition and properties of the ECM
varies according to different tissues and physiological changes, such as aging and in
response to injury.[15, 16] The ECM has many functions including: providing a
physical scaffolding for cell attachment, acting as a reservoir of growth factors,
providing signalling cues that are required to orchestrate cell function in tissue
formation and homeostasis.[16, 17] This extracellular component of the skin can be
divided into: proteoglycans (PGs) and GAGs (Table 1.1) which provide dynamic, and
osmotically active properties of the ECM; and fibrous structural proteins such as
collagens, and laminins, elastin and fibronectin which provide the core structure and
tensile strength of the tissue, enable connection of the matrix components, and regulate
cell function.[12, 15, 16]

Table 1.1 Glycosaminoglycans in human skin extracellular matrix.
Glycosaminoglycans Main disaccharide unit
Heparin

Heparan sulfate

Ref.

L-iduronic acid 2-sulfate (1→4) N-acetyl-D-glucosamine2&6 sulfate
β-D-glucuronic

acid

glucosamine-2 sulfate
6

2-sulfate

(1→4)

N-acetyl-D-

[18]

[19]

Chondroitin sulfate

Dermatan sulfate

Hyaluronic acid

β-D-glucuronic acid β (1→3) N-acetyl-D-galactosamine-4
sulfate
L-iduronic

β-(1→4)/α

acid

(1→3)

N-acetyl-D-

galactosamine-4 sulfate
β-D-glucuronic

acid

glucosamine

β-

(1→4)/(1→3)

N-acetyl-D-

[20]

[21]

[22]

Collagens are the most abundant fibrous proteins within a healthy ECM. Fibrillar
collagens are present in the dermis as collagen type I and collagen type III, represents
about 80% and 10% of the dermal ECM, respectively. These fibrillar proteins are
organized into complex network of long-chain fibres, intermingled with bundles of
elastic fibres and stabilized by the formation of covalent crosslinks, which is a
mechanism fibronectin-dependant. These fibres provide the skin its mechanical
resilience, tensile strength and structural support, as well as regulate cellular
functions.[15] Abnormalities in genes that encode collagen are linked with several
connective tissue diseases including skin disorders.[13] During the early stages of
granulation tissue formation, myofibroblasts synthesise collagen III, which plays a
regulatory role in the assembly of collagen fibrils and determination of the fibril
diameter of collagen I.

In the early stages of the healing cascade, collagen III expression rises more than the
collagen I expression, leading to an increased ratio of collagen I/III from 20% up to
50% collagen III. The collagen I/III ratio decreases to normal levels again during late
stages of the healing cascade. Increased levels of collagen III relative to collagen I in the
late stages of the healing process characterises an immature scar.[13] Abnormal levels
or irregular ratio of types of collagens can affect cellular function apart from the
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mechanical stress imposed by collagen fibrils, which directly affect the healing capacity
of the tissue.[12] Collagen III-deficiency, for example, may lead to severe spontaneous
skin

wounds

with

non-uniform

collagen

fibrils,[13]

promote

myofibroblast

differentiation and more noticeable wound contracture.[12]

Nonfibrillar collagens comprises collagen type IV, VI, VIII, and XIV. Instead of
forming fibrils, nonfibrillar collagens forms reticular networks, that connect cells to the
basement membrane, or support the structural organization of fibrillar collagens.
Collagen IV is found in the basement membrane and promote keratinocyte and
fibroblast migration and support cell adhesion to the basement membrane. Collagen VI
assemblies anchor cells to the connective tissue and has demonstrated to inhibit
fibroblast apoptosis. Collagen VII has demonstrated to play a role in dermal fibroblast
migration and cytokine expression in wound-infiltrating macrophages. Collagen XIV,
on the other hand, has shown to play a role in reducing dermal fibroblast differentiation
and significantly down-regulating fibroblast DNA synthesis while keeping viability and
cell number stable.[12]

Fibronectin is a glycoprotein assembled into a fibrillar network on the cell surface, it
connects cells to collagen fibres by binding to integrin receptors in the ECM, which
leads to modulation of the cell’s cytoskeleton and enable cell migration. Upon tissue
injury, fibronectin mediate homeostasis, and together with fibrin, provides temporary
meshwork which helps to seal the wound and guide invading leukocytes and endothelial
cell to the wound site. In the later stages of the healing cascade, fibronectin is
synthesised by keratinocytes, endothelial, and dermal myofibroblasts and is found in the
dermis and dermal–epidermal basement membrane.[13] Elastin are synthesised by
fibroblasts and smooth muscle cells and found in skin and blood vessels. Elastin also
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regulates various ECM processes, including the recoil and resilience of the skin. In
mature skin, elastin comprises about 3–4% of the dry weight of tissue.[13]

1.4

Wound healing

The disruption of the skin triggers a highly coordinated series of interconnected events
toward the restoration of the injured or lost tissue. The healing process involves an
integrated action of multiple mediators such as ECM molecules, platelets, GF,
inflammatory cells, cytokines, and chemokines; throughout the sequential, yet
overlapping phases of haemostasis, inflammation, migration, proliferation, and
remodelling (Figure 1.2).[4] The first stage of wound healing starts immediately after
injury occurs.[23] It begins with vasoconstriction of damaged vessels, which is caused
by the activity of vasoconstriction factors such as serotonin, thromboxane A2.[24]
Following, the clotting cascade is activated by extrinsic and intrinsic pathways. Fibrin
along with platelets form a temporary network protecting the structural integrity of
vessels, preventing pathogens from coming in,[25] as well as forming a pathway to aid
cell migration. Platelets are early modulators of the healing process. When injury occur,
the platelets in the blood get activated, adhering and releasing numerous proteins, GFs
and cytokines in the injured site, such as platelet derived growth factor (PDGF),
transforming growth factor (TGF-α, TGF-β), basic fibroblast growth factor (bFGF),
insulin-like growth factor 1 (IGF-1), and vascular endothelial growth factor (VEGF).
PDGF is an important growth factor for tissue regeneration, with numerous functions
such as being a chemoattractant for neutrophils and macrophages.[26]
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Figure 1.2 Schematic representation of the different stages of the wound healing
process.
The typical wound healing process can be sectioned into four overlapping phases
hemostasis, inflammation, proliferation and remodelling. Each phase is dominated by
different types of cells responsible for distinct cellular events. The cellular activities are
regulated by various growth factors and cytokines secreted by the cells; MMPs: matrix
metalloproteinases; and ECM: extracellular matrix components.

After bleeding is under control and a barrier is secured, the subsequent inflammation
phase starts. The predominant cells in this phase are phagocytic cells, such as
neutrophils and macrophages.[27] The previous constricted vessel now expands and the
permeability of its walls are increased, facilitating the migration of cells to the wound
area.[28] Neutrophils are recruited by chemotactic factors like thrombin, products of
fibrin decomposition, bacteria, complement (C5a) components, histamine, prostaglandin
E2 (PGE2), leukotrienes, TGF-β, and PDGF.[26] These cells are the first to arrive in the
wound area and are the first line of defence against infection phagocytising and killing
pathogens by releasing proteases and ROS.[29] After 2-3 days in the wound area,
neutrophils are depleted and replaced by monocytes.[23] Macrophages are very
important cells for the healing process because they not only participate in the
phagocytosis process of killing bacteria and removing debris, but also are the major
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source of GFs and cytokines stimulating the proliferation of fibroblasts and collagen
synthesis. [24]

At this stage, the process of rebuilding the damaged tissue is intensified by the
migration and proliferation of fibroblasts, endothelial cells, and keratinocytes. These
cells release mediators that modulate the granulation tissue formation, epithelialization,
and angiogenesis.[30] The temporary fibrin network is replaced by granulation tissue,
which consists of collagen (mainly type I and III), elastin, proteoglycans,
glycosaminoglycan, and non-collagen proteins. These cells are synthetized mainly by
fibroblasts whose activity is regulated by PDGF and TGF-β. Epithelialization, a
multiphase process to reconstruct the epithelium after the injury, comprises of cellular
detachment, migration, proliferation, and differentiation. Angiogenesis restores the
development of ischemic necrosis simultaneously stimulating the tissue repair process.
Endothelial cells migrate and create a network branching into tubular structure
beginning the new blood vessel loop. When tissue is replaced by collagen matrix and
later by scar, the oxygen influx and nutrients decrease significantly. Angiogenesis is
halted and part of the capillaries disintegrate during apoptosis.[31]

During the last phase of the healing process the granulation tissue matures to form a
scar. The maturation process of the granulation tissue comprises the reduction of
capillary amounts by aggregating into bigger blood vessels, lowering the content of
glycosaminoglycans and proteoglycans. Cell density and metabolic activity of the tissue
are also lowered. The proportion of collagen changes (type III collagen content is
converted to collagen type I), the total collagen content increases and its spatial
organization rearrange, forming more covalent cross-links, which leads to increased
tensile strength of the tissue. This stage can last months to years and the new tissue
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could reach from 50-80% of the some of its original healthy functions, depending on the
severity of the initial wound.[31]

1.5

Scar formation

Normal scar formation is the body’s natural response to tissue injury and does not
develop until after the wound has completely healed. During the healing process, dermal
ECM composition is remodelled - dense ECM network comprised mostly of collagen
gradually replace the original loose and hydrated ECM. A visible scar will be formed if
a wound takes more than 3-4 weeks to be re-epithelialized. The scar tissue loses its
original strength and functionality as there will be less blood vessels, which will limit its
blood irrigation, and denser ECM network will make the tissue less tolerant to shape
change. Impaired wound healing and abnormal scar formation is a huge cause of
morbidity as cosmetic/function impairment, and mobility limitation due to scar
contraction and pain, deeply affect the patient quality of life. Scar tissue exhibit
disturbance of the alignment of collagen fibres - collagen fibres are aligned in a single
direction parallel to the skin, differently from healthy skin where collagen fibres are
organised in a random basket weave pattern. Scar tissue is formed by the same ECM
molecules as the tissue they replace, however, the levels of those molecules are altered
in scar tissue, for example, dermal scar tissue displays higher levels of collagen I and
III, fibronectin, and laminin.[13]

Scars can be classified according to their clinical behaviour and physical aspects.
Atrophic scars are characterised by an indented recess of the skin due to loss of
underlying supportive structure like muscle or fat, and it is often a result of severe acne
or chickenpox. Hypertrophic scars are characterised by the excessive deposition and
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alterations of collagen and other ECM proteins, which gives the skin raised and often
red appearance. It is often developed post thermal or traumatic injury. Keloids are also
raised and red in appearance, but differently than hypertrophic scars, it grows outside
the original wound area. Keloid scars are characterised by the excessive deposition of
collagen and high ratio of collagen I/III – (about 17:1) compared to normal scars (about
6:1), which may be a result of high proliferative activity of keloid fibroblasts.[13]
Figure 1.3 shows the histological assessment of scars highlighting the epidermal
abnormalities in different scars.

Differently from the adult skin wound healing process that involves fibrosis and
scarring, foetal wound healing is able to fully regenerate the skin and restore the normal
ECM architecture, strength and function, resulting in a scarless phenotype. Even though
the mechanism of the foetal healing is still unknown, studies have reported different
inflammatory response, cellular mediators, cytokines, growth factors, and ECM
modulators and structures between postnatal and foetal wound repair.[13] Key
differences in the foetal healing process that may influence its remarkable regeneration
ability are the concentration of collagen I and III, and the ratio of collagen III/I. It has
been reported that foetal ECM is rich in collagen III and hyaluronic acid (HA), and even
though collagen I is the major ECM component, like in adult skin, the total amount of
collagen I is lower in foetal skin compared to adult skin. The ratio of collagen III/I in
foetal skin is also higher, having collagen III comprising 30–60% of the total collagen
compared to 10–20% in adult skin.[13]
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Figure 1.3 Histological assessment of scars.
Haematoxylin and eosin staining images of (a) Epidermis, (b–g) Dermis of (b)
normotrophic scar (Nscar), (c) young immature scar (Yscar) with (g) adjacent normal
skin (Nskin), (d) hypertrophic scar (Hscar), and (e) keloid scar (Kscar) with (f)
surrounding‐normal‐skin (sNskin). Scale bar = 100 μm. The dashed line in (e) indicates
the border between ‘keloidal collagen’ (left) and normal scar dermis (right). [32]

1.6

Cutaneous wounds

As the skin is permanently exposed to the external atmosphere, it is constantly
susceptible to mechanical and chemical insults.[33] According to the Wound Healing
Society, a wound can be described as the result of disruption of normal anatomic
structure and function of the skin.[34] Wounds can be sorted into various
categories.[35] Based on their time frame of healing, wounds can be clinically classified
as acute and chronic. Acute wounds normally proceed by following a timely and orderly
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healing cascade

of

haemostasis, inflammation,

migration, proliferation, and

remodelling, achieving functional and anatomical restoration of the skin, with minimal
scarring.[35] Completely healing within the expected healing time frame of 8 to 12
weeks.[36] The primary causes of acute wounds include: abrasions; penetrating caused
by knives, gun shots and surgical incisions; as well as burns, chemicals and thermal
sources.[37]

Complex wounds, or hard-to-heal wounds, is a term used to describe wounds that may
involve multiple tissues, where healing is prolonged/disrupted or fails completely, often
complicated by comorbidities or infection.[38] Impaired wound healing and abnormal
scar formation is a significant cause of morbidity as cosmetic/function impairment, and
mobility limitation deeply affect the patient quality of life.[13] Chronic wounds do not
follow the conventional stages of healing in an orderly and timely manner[27]
remaining open for more than 12 weeks and/or often reoccurring.[39] Chronic wounds
can be classified as diabetic ulcers; venous and arterial ulcers; and pressure ulcers.[40]
Despite differences in ethology at the molecular level, chronic wounds share lack of
balance between pro- and anti-inflammatory factors such as cytokines, growth factors
(GF), proteases, and metabolically competent leading to excessive and prolonged
inflammation, persistent infections, and the inability of dermal and/or epidermal cells to
respond to reparative stimuli.[41] For this reason, it is important to re-establish the
balance of cytokines, GF, proteases, and metabolically competent cells in order to
restore the skin healing ability.[27]

Burn injury is a significant cause of morbidity and mortality related to the depth and
surface area of the skin involved.[42] Due to the disruption of the barrier integrity, the
risk of systemic infections in burn patients is high, which accounts for most of the
15

associated death. To improve patient outcome, covering the wound in a timely manner
is key to reducing infection and to restoring the barrier function. Historically the drive
for a tissue engineered solution was the need to repair the skin in massive burn injuries.
The use of laboratory based tissue expansion in the form of cultured epithelial
autografts (CEAs) was first clinically used in 1982.[43] Further development has been
made by shortening the lengthy time needed for the preparation of CEAs through
delivering autologous cell suspension using a spray system.[43-46] However, for fullthickness burns, the healing is less ideal as CEAs address only the epidermal repair. The
development of dermal scaffolds has facilitated in situ tissue guided regeneration of the
dermal elements to repair full-thickness wounds when the donor sites for traditional skin
grafts are compromised.[42, 47]

1.7

Current strategies for skin regeneration

The treatment of cutaneous wounds is a critical issue in healthcare, requiring deep
understanding of several factors affecting the healing process, such as the wound cause
or type (burn, ulcer, acute and chronic wound), the wound depth (which can be
classified as epidermal, superficial partial-thickness, deep partial-thickness and fullthickness wounds), the patient’s health condition like diabetes and persistent infections,
as well as the level of the exudate.[4, 26] One of the main goals and biggest challenges
of current skin wound treatments is to stimulate fast wound closure coupled with
optimal aesthetics and functional regeneration.[48] To date, a great variety of wound
care products are available for the treatment of different types of skin wounds. Table 1.2
summaries some of the current and emerging strategies available for treating skin
wounds.
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Table 1.2 Current and emerging strategies for the treatment of skin wounds.
Adapted from [4]
Treatment
Autografts

Allografts
Creams,
solutions, and
ointments
Traditional
dressings

Modern
dressings

Tissueengineered skin
substitutes

Advantages
‘Golden standard’ in skin regeneration;
good adhesion to the wound bed;
provides pain relief; reduced rejection
Temporary prevention of wound
dehydration and contamination;
incorporate into deep wounds
Ease of use; provide disinfection,
cleaning, and debridement; not expensive
in general
Not expensive; provide a protective
barrier against the penetration of
exogenous microbes
Create and maintain a moist wound
environment; can be made from a wide
range of materials with different
properties; ability to hydrate the wound
and remove excess exudate
Promote the regeneration of dermis and
epidermis; prevent fluid loss and provide
protection from contamination; may
deliver extracellular matrix components,
cytokines, growth factors and drugs to
the wound bed, enhancing the healing
process; can be used in combination with
autografts

Limitations
Limited availability of donor sites;
induce scar formation; patient morbidity;
lengthy hospital stays
Limited availability; may lead to
immune rejection; transmission of
diseases
Limited skin regeneration; short
residence time on the wound (require
frequent administrations)
High absorption capacity; do not provide
a moist environment; adhere to the
wound bed; may inhibit the healing
process
More expensive; low adhesion to the
wound bed; inability to promote the
regeneration of lost skin, in particular
the dermal layer
High manufacturing costs; difficult
handling; poor adhesion to the wound
bed; possibility of immune rejection and
transmission of diseases (allogeneic skin
cells); inability to promote the
regeneration of full-thickness wounds;
poor vascularization; impossibility of
reproducing skin appendages

Complex wounds are incapable of steering cellular events toward tissue regeneration
and healing; therefore, they require skin substitutes to address these limitations.
Traditional skin grafts including autografts, allografts and xenografts face significant
limitations regarding availability, safety, and risks of morbidity.[49] For instance,
autologous skin grafts include split-thickness skin graft (STSG) and full-thickness skin
graft (FTSG). STSG, which contain the epidermal compartment plus a portion of the
dermal compartment, are used in the treatment of extensive injures, and full-thickness
burns. The main drawback of this type of graft is the poor cosmetic outcome with
significant scarring and lack of adnexal structures.[50] FTSG, which contain the
epidermal, dermal and subcutaneous compartments are the gold standard procedure in
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cutaneous reconstruction and wound coverage. However, these grafts also have intrinsic
and extrinsic limitations such as limited donor site availability, limited expansion
capability and limited graft survival.[51] These issues are especially prominent when a
large piece of skin graft is needed, which drives the development of skin tissue
engineering and synthetic skin substitutes.

Skin regeneration via transplantation of cellular skin substitutes, using autologous or
allogenic cells, has shown a broad variety of outcomes for temporary or permanent
wound coverage.[52] Its therapeutical effect relies on the ability of cells to selfassemble to form a neo-tissue, and in the production of signalling molecules and ECM
to promote healing.[43] Traditional cell therapies involves the combination of fibroblast
and/or keratinocytes with biodegradable scaffolds, or fluid solutions for manual delivery
of cells.[43] For example, Apligraf® is composed by a type I collagen-based dermal
matrix populated with allogenic fibroblasts and an epidermal compartment composed of
top-seeded keratinocytes.[53] DermaGraft® is a polyglactin-910 or polyglycolic acidbased dermal matrix populated with human foreskin fibroblasts.[54] EpiCel is a sheet of
cultured keratinocytes, from an autologous source.[43] ReCell is cell suspention spray
which contains a mixed population of cells such as keratinocytes, fibroblasts,
Langerhans cells and melanocytes.[55, 56] Limitations of these traditional therapies
include poor durability, inability to reproduce skin appendages,[57] and lack of
spatiotemporal control in cell delivery to form skin-mimicking layered structures.[58,
59] For this reason, traditional wound care and closure products are being increasingly
replaced by more advanced wound treatments. Attempts to decrease the length of stays
at acute care hospitals to reduce surgical healthcare costs and the rising inclination
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towards products that enhance therapeutic outcomes are driving the demand for state-of
the-art wound care and closure products.[4]

Growth factors are soluble proteins capable of modulating a variety of cellular events
important for the healing process.[60] Deficiency of various growth factors have been
reported in chronic wounds and imparted wounds, including reduced levels of TGF-β,
EGF, FGF, VEGF, and PDGF.[61] Commercially available growth factors-based
preparations for external use includes: Becaplermin, recombinant human PDGF for
treatment of DFUs;[62-64] recombinant human bFGF for treatment of burn wounds and
diabetic leg ulcers;[65] as well as recombinant human EGF for treatment of DFUs.[6669] Although topical administration of human-recombinant growth factors has been
approved for clinical use, reported studies have shown conflicting evidences on the
efficacy of topical growth factor in improving healing.[70] Some of the factors that
could be limiting the therapeutical efficacy of growth factors includes low stability,
rapid elimination by exudation in the wound bed, high degradation rate[61] or failure to
provide enough stimulus to initiate the complex cascade of the healing process.[71] In
order to improve the effectiveness of growth factors therapies, several growth factor
delivery systems have been proposed for the treatment of acute and chronic wounds.

1.8

Compelling needs for advanced wound healing products

Wounds, more specifically chronic wounds, are recognised as a silent epidemic as they
have been a major contributor to mortality, morbidity and permanent disability
worldwide.[72] The increase in the aging population coupled with prevalence of
lifestyle diseases and chronic wounds; increase of complex surgical procedures and
introduction of government initiatives to decrease lengths of hospital stays are some of
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the factors driving the demand of the advanced wound care market. The global wound
closure and advanced wound care management market is estimated to reach $26 million
by 2026.[73] The global tissue engineered skin substitutes market is valued around $131
billion (2020) and is estimated to reach $335 billion by 2025.[74] Burn is one of the
leading causes of non-intentional death/injury worldwide with an estimated of 180,000
deaths every year,[75] in the United States alone with an estimated of 40,000
hospitalizations related acute burn injuries occurred in United States in 2016.[76] A
retrospective analysis of the national health insurance program in the United States 5%
dataset (2014) showed that in the US, about 8.2 million patients presented at least one
type of wound/related infection in 2014, and the treatment cost was conservatively
estimated in about $32 billion.[77] In Australia, the precise health and economic burden
of wounds is unknown, however, it has been estimated that about 400,000
hospitalizations and residential care settings occur in Australia each year. From those
cases, pressure wounds represent 84%, venous leg ulcers (VLUs) 12%, diabetic foot
ulcers (DFUs) (3%) and arterial insufficiency ulcers (1%). General wound treatment
costs was estimated in about AUD$3 billion a year, which represents approximately 2%
of the Australian national healthcare expenditure.[78]
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1.9

Bioprinting technology

Figure 1.4 Schematic illustration of 3D bioprinting capabilities reported for skin
bioprinting.
(a) Inkjet bioprinting: the ejection of bioink droplets is controlled by either a thermal or
piezoelectric actuator where pressure pulses are generated to regulate the valve-opening
time. (b) Extrusion bioprinting: driven by either pneumatic pressure, or an advancing
piston or screw, highly viscous bioinks are extruded in the form of continuous filaments
into direct contact with the substrate. (c) Laser-assisted bioprinting: a laser provides the
driving force to propel the cell-laden bioink onto a collector platform. (d) Digital light
processing-based bioprinting: the photosensitive polymer precursor in a container is
cured layer-by-layer by projected and patterned UV and/or visible light generated by a
digital micromirror device.[79]

Tissue engineering is an interdisciplinary field which applies principles and
technologies in engineering, materials science, cell biology, and biomedicine to restore,
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maintain, or improve biological tissues.[80] One of the tissue engineering approaches
for wound healing application involves the development of functional yet biocompatible
three-dimensional (3D) skin substitutes consisting of biomaterials and living cells to
support and guide the regeneration of injured or lost tissue.[80] Tissue engineering
techniques including bioprinting, photolithography, and electrospinning[81] have been
proposed to overcome existing limitations of traditional skin wound treatments.[11]
Among them, bioprinting is rapidly emerging as a promising technique for precise
spatial manipulation of living cells, bioactive molecules and functional components,
with the potential to mimic the complex physiological microenvironment of tissues and
organs.[81]

Bioprinting is an additive manufacturing technique based on computer-aided-design
(CAD), wherein living cells and biomaterials are dispensed in a temporal and spatial
controlled fashion.[6] A complex 3D microenvironment can be fabricated by using a
bioprinting approach, in which the cells can be encapsulated into hydrogel to mimic
natural ECM of a specific tissue; thereby overcoming various limitations faced in tissue
engineering and regenerative medicine.[6] Common bioprinting strategies used to
produce tissue scaffolds include inkjet printing, extrusion printing and laser-assisted
bioprinting.[81] In this thesis, extrusion-based bioprinting will be further described, as
this was the method chosen for the fabrication of tissue-like structure, which will be
presented in the following chapters.

1.9.1

Extrusion Bioprinting

Extrusion-based bioprinting has become one of the most widely used bioprinting
platform due its great versatility and feasibility in the fabrication of scaffolds for tissue
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engineering. Some of the advantages of this method are its relatively low cost; capacity
to dispense a wide array of biomaterials and cells; ability to dispense viscous inks (30
mPa s-1 to > 60 kPa s-1) with high cell density; and fast deposition speed, which is often
used to produce large-scale scaffolds. By using extrusion-based bioprinting platforms,
tissue scaffolds can be developed with biological and mechanical properties appropriate
for the restoration of damaged-tissue.[80] Extrusion-based bioprinting platform is
composed of a fluid-dispensing head (or multiple fluid-dispensing heads) and an
automated robotic system. During bioprinting, the dispensing head is moved along X-YZ axes depositing cylindrical filaments of desired 3D designed model layer-by-layer.
This rapid fabrication technique provides better structural integrity due to the
continuous deposition of filaments.[82] Extrusion-based methods can be classified into
three categories: pneumatic, piston, and screw-based bioprinting. In piston- or screwbased systems, the ink is mechanically pushed by a linear moving piston or a rotating
screw-driven configuration.[80] Pneumatic-based bioprinting utilizes pneumatic
pressure to extrude the ink from the nozzle at a controllable volume and flow rate. The
deposition accuracy highly dependent on the flow properties of the ink and can be
significantly affected by the viscosity of the ink solution.[83]

1.9.2

Bioinks

Hydrogel-based bioinks which can encapsulate living cells and bioactive molecules are
commonly used for bioprinting process (Figure 1.5).[81] The hydrogels used for tissue
engineering application are predominantly from natural biopolymers. High water
content hydrogels provide an optimal environment for incorporation of cells and
bioactive molecules, because they can provide an instructive, aqueous 3D matrix,
mimicking the native ECM. The chemical signals present in these hydrogels, lead to
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high cell viability and proliferation rates.[84] Understanding the performance of
materials is necessary for developing bioink formulation. The basic properties of an
optimal biomaterial for tissue regeneration are biocompatibility with the target tissue;
biodegradability rate compatible with native ECM; non-cytotoxicity; and nonimmunogenicity.[11] In addition to these intrinsic biological properties, it is extremely
important to assess the physicochemical properties of the hydrogel ink to determine its
suitability for printing under the conditions imparted by the chosen biofabrication
approach. The main parameters that determine the suitability of a hydrogel ink includes
rheological behaviour and crosslinking mechanisms.[84] A common way to improve
printability of hydrogels is by modulating the polymer concentration or crosslink
density.[85]

Figure 1.5 Schematic representation of a bioink components.[86]
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1.9.3

Crosslinking Mechanisms for Hydrogels

The gelation achieved through different crosslinking mechanism is used to hold the
structural shape of a printed hydrogels. The crosslinking can either be physical,
chemical, forming of covalent chemical bonds, or combination of both processes.
Physical crosslinking mechanisms rely on non-chemical interactions of high molecular
polymer chains, such as ionic interactions, hydrogen bonds, or hydrophobic interactions.
Chemical crosslinking mechanisms forms hydrogels through irreversible covalent
bonds, which can provide high mechanical strength to the printed construct.[84] Table
1.3 adapted from Malda et al. summarizes the crosslinking strategies and compares their
advantages and disadvantages.

Table 1.3 Crosslinking strategies for biofabrication. Adapted from[84]
Crosslinking
strategies

Advantages

Disadvantages

Ionic

Reversible interactions ensure constant
viscosity during printing,
Excellent compatibility with biological
systems.

Stereo
complex

Reversible interactions ensure constant
viscosity during printing,
Excellent compatibility with biological
systems.

Requires additional crosslinking
agent and/or post-processing
crosslinking,
Mechanically weak constructs,
Relatively slow gelation,
Relatively high viscosity of the
building blocks
Requires additional crosslinking
agent and/or post-processing
crosslinking
Mechanically weak constructs

Physical

Thermal

Chemical

UV

Wet
chemical

Reversible interactions ensure constant
viscosity during printing
Rapid reassembly to gels after printing
Excellent compatibility with biological
systems
Polymerisation through irradiation during
printing does not affect viscosity during
printing in the nozzle
Allows for post-processing crosslinking
(stabilization) of mechanically weak
physically crosslinked hydrogel constructs
No need for irradiation or other further
stabilization - Mechanically stable
constructs
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Requires post-processing
crosslinking
High reaction rates necessary as
polymerisation needs to be
completed between nozzle and
deposition
May involve exposure of
constructs to irradiation
Irradiation may affect embedded
cells
May require (potentially
harmful) crosslinking agent
A trigger for chemical reactivity
with required stringent control

of crosslinking kinetics is
needed to avoid viscosity
change in the nozzle throughout
printing time but ensure
crosslinking between nozzle and
deposition

Physical crosslinking is the most prominent method used to produce crosslinked
hydrogels through biofabrication processes,[87] because of its excellent compatibility
with fragile molecules and with living cells. Physical crosslinking forms non-covalent
interactions between hydrophilic polymer chains preventing hydrogel dissolution in an
aqueous environment.[84] The major drawback of physically crosslinked hydrogels is
their poor mechanical properties, which may cause instability, difficulties in handling
and poor overall performance. For this reason, increasing attention has been driven to
hydrogels which can be pre-crosslinked prior to printing allowing better filament
deposition, and chemically crosslinked after printing by exposure to radiation or postprocessing reaction of complementary chemical groups to fixate and stabilize the
printed structure.[84]

1.9.4

Biomaterials

Material selection is one of the most important steps of the tissue scaffold biofabrication
because they provide a structural interface required for interaction between ECM, cell
and growth factors.[88] Synthetic polymers commonly used in bioink formulations
include polyethylene glycol (PEG)[89], pluronic[90], poly(vinyl pyrrolidone) (PVP)[91]
and polycaprolactone (PCL)[92]. Materials modified to include cell-instructive
molecular motifs are promising candidates with the ability to tailor cell-material
interactions. For example, Lutolf et al. engineered cell-responsive PEG hydrogels that
contain specific amino acid sequences cleavable by MMP. Human foreskin fibroblasts
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were shown to be able to breakdown and remodel the densely crosslinked PEG network
as a result of the enzymatic activity of secreted MMP.[93]

Naturally derived materials include collagen, gelatin, albumin, thrombin, fibrinogen;
polysaccharides such as chitosan, chitin, cellulose, and etc (Table 1.4).[11] These
natural biopolymers are being widely used for tissue engineering application because of
their similarities to the ECM, biological characteristics and inherent cellular interaction.
However, inadequate mechanical properties or poor processability of currently available
biopolymers are limiting their application to a certain extend.[88] Therefore,
improvements on the properties of biopolymers, composites with natural and synthetic
materials, and discovery of new biomaterials are needed to increase the available
materials for biomedical applications. Table 1.4 summarizes examples of the recent
bioinks used for bioprinting as related to skin regeneration. The range of bioinks for
inkjet printing is limited due to the low viscosity requirements. Here, GelMA and
growth factor-rich biomaterials will be further discussed as these biomaterials were used
in bioink formulations in the following chapters.

Table 1.4 Review of biomaterials used as bioink components for 3D printing of skinlike structures.
Biomaterial components
Collagen I
Collagen
PEG-based BioInk
D: collagen
E: PVP-based bioink
Collagen I
Fibrinogen/collagen I
fibrinogen/collagen I; plasma
thrombin
Chitosan/PEG
Collagen I
Collagen
Human plasma containing fibrinogen

Printing
Inkjet
Inkjet
Inkjet
Inkjet

Cells
HDFa / HEKa
HDFn / HaCaT
HDF / HEK
HDF / HEK / HEM

Ref
[94]
[95]
[96]
[91]

Inkjet
Inkjet
Inkjet

HDFn / HEKn / HEMn
AFS / BM-MSC
HDF / HEK

[97]
[59]
[58]

Inkjet
Laser-assisted
Laser-assisted
Extrusion

HDFn
NIH3T3 / HaCaT
NIH3T3 / HaCaT
HDF / HEK

[98]
[99]
[100]
[101]
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Gelatin/chitosan
Alginate/gelatin
Gelatin/alginate/fibrinogen
Chitosan/D-(+)raffinose pentahydrate
GeMA/collagen, tyrosinase-doped
Silk fibroin/gelatin
Pectin methacrylate/peptide RGD
Human platelet lysate/GelMA
Ulvan methacrylate/gelatin
Ulvan methacrylate/GelMA/gelatin
Alginate/honey

Extrusion
Extrusion
Extrusion
Extrusion
Extrusion
Extrusion
Extrusion
Extrusion
Extrusion
Extrusion
Extrusion

HDFn
HDF
NIH3T3/GFP / HEK
HDF / HaCaT (seeded)
HDF / HaCaT / HEM
HDF / HEKa
HDFn
HDF
HDF
HDF
NIH3T3

[102]
[103]
[104]
[105]
[106]
[107]
[108]
[109]
[110]
[111]
[112]

Decellularized dermis/alginate

Extrusion

NIH3T3

[113]

Collagen I/PCL mesh

D: Extrusion
E: Inkjet
D: Extrusion
E: Inkjet

HDF / HEK

[114]

HDF / HEK / HUVEC / HPAd

[115]

D: Extrusion
E: Inkjet
D: Extrusion
E: Inkjet
BM: Inkjet
Inkjet

HDFn / HEKn / ADMSC / hEPC

[116]

D: skin-dECM/fibrinogen
HD: adipose-dECM/fibrinogen
V: Gelatin, glycerol/thrombin
dECM

D: Gelatin/fibrinogen/collagen
HDFn / HEKn
[117]
I/elastin
BM: Laminin/entactin
D: Collagen
HDF / HEK / hEC / hPC-PL
[118]
E: Culture medium
Silk fibroin/4-arm PEG
DLP
NIH3T3 / HEK
[119]
GelMA/HA-NB
DLP
HDF / HUVEC
[120]
Note: D: Dermal compartment; E: Epidermal compartment; BM: Basement membrane; HD: Hypodermal
compartment; and V: Vascular compartment. DLP: Digital light processing. HDF: Primary human dermal
fibroblasts (a:adult/n:neonatal); HEK: Primary human epidermal keratinocytes (a:adult/n:neonatal);
HaCaT: Immortalized human keratinocytes; NIH3T3: Immortalized non-tumorigenic murine fibroblast;
HEM: Human epidermal melanocytes (n:neonatal); AFS: Amniotic fluid-derived stem cells; HPAd:
Human preadipocytes; HUVEC: Human umbilical vein endothelial cells; BM-MSC: Bone marrowderived mesenchymal stem cells; ADMSC: Adipose-derived mesenchymal stem cells. hEPCs: Human
endothelial progenitor cells; EC: Human endothelial cells; hPC-PL: Human pericytes from placenta.

1.9.4.1 Gelatin methacryloyl (GelMA)

GelMA is a denatured type of collagen that has been widely used as a versatile matrix
for tissue engineering scaffolds.[121-124] GelMA’s inherent thermo-responsive
characteristics and pseudoplastic behaviour facilitate filament deposition during the
extrusion process and reduce nozzle-clogging,[125] whilst protecting cells against
excessive shear stress.[126] Moreover, its photo-crosslinkable methacryloyl groups
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enable irreversible shape fixation of the final printed construct.[127] GelMA hydrogels
exhibit remarkable tunable physical and chemical properties, which makes them ideal
candidate for skin tissue printing.[124] Several GelMA bioinks composites have been
proposed for skin bioprinting. For example, Shi et al. describe a bioink composite made
of GelMA and collagen doped with tyrosinase for the 3D bioprinting of living skin
tissues.[106] Zhou et al. reported a bioink composite (GelMA/HA-NB/LAP) to print
functional living skin tissue using digital light processing (DLP)-based 3D printing
technology.[120] Even though it has proven to be a promising material for regenerative
medicine and tissue engineering application, GelMA faces similar drawbacks to
collagen as lacking mechanical strength and being subject to fast degradation. A general
strategy to overcome these drawbacks is to make use of a secondary material without
much elevation in the mechanical stiffness.

Figure 1.6 Gelatin methacryloyl (GelMA) synthesis reaction. Adapted from [128]

1.9.4.2 Growth factor-rich biomaterials

This category includes platelet bioproducts, such as platelet-rich plasma and platelet
lysate. Platelet bioproducts are growth factor-rich serums derived from human platelets.
Platelet bioproducts are a cost-effective source of growth factors containing high
concentration of several relevant factors in wound healing, including PDGF, bFGF,
VEGF and TGF-β.[129, 130] They can be obtained from an autologous source for
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application in personalized medicine. Autologous platelet derived products present
reduced risk of adverse immune reactions, but the volume of product produced from an
autologous material may not be enough for clinical application, moreover, issues related
to lack of standardization, and growth factor heterogeneity may lead to variations in the
therapeutic efficacy. On the other hand, allogenic platelet derived products can be
pooled to reduce individual donor variation. It can be automatized and standardized for
production in large scale, however, it has higher risk of contamination and immune
reaction.[71, 131, 132]

Figure 1.7 Schematic representation showing the PL preparation
from whole blood collection, activation/lysis of the platelets, and release of cytokines or
growth factors. PRP, platelet-rich plasma; PL, platelet lysate.[133]
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The therapeutical integration of 3D printing and growth factors have shown
improvement in the manufacturing speed process for personalized approach, enable
spatial dictation and controlled release of growth factors.[134] Xiong et al. reported the
incorporation of FGF-2 into printed gelatin-sulfonated silk composite scaffold. FGF-2
shown to support re-epithelialization and promote expression of blood vessel related
proteins such as smooth muscle alpha-actin (α-SMA) and CD31 in vivo.[52] Moreover,
Wan et al. demonstrated that silver and PDGF-ββ co-loaded 3D printed scaffolds
improved in vivo re-epithelialization, granulation tissue formation and angiogenesis in
type II diabetic mice.[135] Intrinsic characteristics of the delivery vehicle material also
heavily influence the release kinetic of growth factors. For this reason, material whose
affinity with growth factors, and tuneable mechanical, physical, degradation properties
are preferred.[120] Novel 3D printing strategies for controlled and smart release of
biologically relevant factors in a spatiotemporal fashion may provide more effective and
safe alternatives as well as great benefits to patients in the near future.

1.10 Electrofluidic approach

With increasing complexity of surgical procedures, appropriate post-operative wound
management is crucial to prevent complications and achieve the best aesthetical and
functional healing possible. Therefore, in addition to the hydrogel-based delivery
system introduced earlier, it is also of interest to explore an electrofluidic approach
using surgical sutures for post-surgical wounds. Thread and textiles have recently
gained considerable attention as low-cost substrates for microﬂuidics and biosensor
applications, based upon their mechanical strength and the ability to facilitate and direct
fluid movement. Fluid flow in threads arise from wicking processes as a result of
capillary forces generated within the gaps between directionally aligned fibres.[136]
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Threads have been used for variety of applications, including bioanalysis,[137-143] and
embedded in a hydrogel as a network for chemotaxis studies[144] or multilayer feeding
of cell cultures.[145] Threads can be readily integrated into a gel to provide an easy and
robust way to transport liquid in or out of a gel. Direct application of biomolecules onto
a thread or yarn is trivial and enables dispatch at a targeted location.[138] Therefore,
chapter 4 will introduce a novel electrofluidics system for precise control and
manipulation of fluids on threads/sutures to deliver biomolecules into and throughout a
gel, via control of an applied electric field, to provide a simple approach involving no
moving parts or pumps. This work was possible through a collaboration between ARC
Centre of Excellence for Electromaterials Science (ACES) nodes, the University of
Tasmania (UTAS) and the University of Wollongong (UOW) node. Even though the
theme of chapter 4 slightly diverges from the thesis main theme, this system was
designed with the aim to be used for would healing application and be potentially
integrated with the bioprinted PLGMA matrix in surgical wounds.
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Figure 1.8 Incorporation of threads to electrofluidic and microfluidictechnology for
biorelated studies.
(A) Acoustically driven fluid into a thread network embedded in transparent hydrogel.
(B) pH-sensing system communicating with a smart phone via a Bluetooth platform. (c)
The use of knotting to link different thread materials to trap bacteria for urinary tract
infection. [146]
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1.11 Research aim

This thesis will investigate two innovative approaches to meet the challenges of current
wound healing treatments. The first approach will be introduced in chapters 2-3 and will
detail the development and initial in vitro characterisation of a novel 3D multifunctional
bioprinted skin platform based on platelet lysate. The hypothesis is that by developing a
3D printed platform containing multifunctional biomaterials and skin cells, this platform
could be used to deliver cells and growth factors to the wound site, while providing a
supportive network that mimics the native ECM for skin cells to infiltrate and thrive.
The second approach will be introduced in chapter 4 and will detail the design
development and proof-of-concept study of a novel electrofluidic approach for
controlled delivery of bioactive molecule into soft tissue model using threads/surgical
sutures. The hypothesis is that by using surgical sutures and electric field to deliver
bioactive species into tissue-like materials, delivery of relevant drugs for wound healing
could be finely controlled by alternating the field on/off.
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2 Chapter

In vitro characterization of 3D printed platelet lysate-based bioink
for potential application in skin tissue engineering

The work presented in this chapter was adapted from the manuscript published at the
Journal Acta Biomaterialia S1742-7061(21)00048-9 (2021). doi:
10.1016/j.actbio.2021.01.021 by Daikuara LY, Yue Z, Skropeta D, Wallace GG. In vitro
characterisation of 3D printed platelet lysate-based bioink for potential application in skin
tissue engineering.
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2.1

Introduction

Platelet derived products have been gaining considerable attention lately as an
autologous source of biologically active molecules[71] and have been proposed for
regeneration of skin wounds,[147-150] bone,[151] cartilage,[152] cornea[153] and
ligaments[154]. Platelet lysate (PL), obtained by disruption of platelets, has been used
in the clinic as a topical administration or local injection to damaged tissue.[155]
Despite the optimistic scenario, the major drawback of these approaches is the poor
retention of bioactive molecules to the wound site due to rapid access of these
molecules to the blood stream and excessive enzymatic degradation, hindering the
effectiveness of the therapy.[155] Since The therapeutical outcome of GFs are known to
be dependent on their spatial distribution. Controlling the delivery of GFs both spatially
and temporally is essential for successful translation of GFs as a regenerative medicine
tool into clinical practice.[61] In order to meet these challenges, the combination of
bioprinting technology and platelet bioproducts has been proposed for the fabrication of
functional tissue engineering models[156, 157] Bioprinting is an attractive approach to
fabricate effective 3D hydrogel-based delivery systems that can mimic the function of
the target tissue, protect GFs from degradation and enable spatial-temporal GF delivery.

As the interest for PL rises, more studies about the incorporation of PL into different
platforms for tissue regeneration have been reported,[155, 158] however, its use as a
bioink component for wound healing application has yet to be explored. Therefore, as
the initial step towards the biofabrication of a complex skin equivalent which can codeliver GFs and skin cells for complete functional regeneration of skin, the present work
focused on the development of a multifunctional bioink for the fabrication of a 3D
printed dermal equivalent and in vitro investigation of its potential to deliver relevant
51

GFs while providing support for cell proliferation and deposition of extracellular matrix
(ECM). Herein, we demonstrated that by direct assembly of biologically active GFs
into a 3D polymeric network, we were able to achieve controlled release of GFs, at the
same time, immobilized GFs in the matrix showed a positive effect on cell behaviour.
The proposed platform was evaluated regarding its physical, rheological, and
mechanical properties. The cytocompatibity of the bioink formulation were firstly
assessed by means of in vitro cellular viability, proliferation, morphology, and ECM
production using human dermal fibroblasts (HDFs), cells of great importance in the
wound healing process and commonly used in bioengineered dermal equivalents. [159161] Potential application of the proposed bioengineered skin equivalent includes use in
the clinic for wound healing, providing temporary wound coverage while supporting
new tissue formation; and as an ex-vivo skin model for animal-free testing.
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2.2

Experimental Section

2.2.1

General materials

Key materials used in this chapter are introduced in detail as follow.

Materials

Source

Cat Number

Human dermal fibroblasts

Cell Applications

-

Human platelet lysate (PL)

PL BioScience

-

Heparin

Sigma-Aldrich

H3149

Gelatin (porcine skin, Type A, 300 Bloom)

Sigma-Aldrich

G2500

Methacrylic anhydride

Sigma-Aldrich

P5927

Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP)

Sigma-Aldrich

900889

DMEM, high glucose, HEPES

Sigma-Aldrich

D1152

Fetal Bovine Serum

Interpath

SFBSN2

Penicillin/Streptomycin

Gibco

15140122

PrestoBlueTM

Invitrogen

A13262

Calcein AM

Invitrogen

C3099

Propidium iodide (PI)

Invitrogen

P3566

Donkey serum

Merck

S30

Paraformaldehyde

Fluka

76240

PBS tablet

Sigma-Aldrich

P3813

Triton X-100

Sigma-Aldrich

T8532

Collagenase (type I)

Sigma-Aldrich

C2674

Rabbit polyclonal anti-collagen I

ABCAM

ab21286

Rabbit polyclonal anti-collagen III

ABCAM

ab7778

Rabbit polyclonal anti-elastin

ABCAM

ab21610

Rabbit polyclonal anti-fibronectin

ABCAM

ab2413

Alexa Fluor 488

Invitrogen

a21206

DAPI

Invitrogen

D1306

AurumTM Total RNA 96 Kit

Bio-rad

7326800

iScript RT Supermix, 100 rxns

Bio-rad

1708841

SYBR® Select Master Mix

Life Technologies

4472897

Ink formulation

Characterisation

Antibodies

PCR
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ELISA
DuoSet ELISA development kit PDGF-AB

R&D Systems

DY222

DuoSet ELISA development kit VEGF

R&D Systems

DY293B

DuoSet Ancillary Reagent Kit 2

R&D Systems

DY008

Simple Step ELISA kit PDGF-BB

ABCAM

ab184860

Simple Step ELISA kit EGF

ABCAM

ab217772

Simple Step ELISA kit FGF

ABCAM

ab219636

ELISA kit TGF-β1

ABCAM

ab108912

2.2.2

Cell culture

Human dermal fibroblasts (HDFs; Cell Applications) were cultured in Dulbecco’s
Modified Eagle Medium (DMEM, high glucose, HEPES; Sigma-Aldrich) supplemented
with 10% v/v fetal bovine serum (FBS), 1% v/v penicillin/streptomycin (P/S) under
standard culture conditions in a humidified atmosphere with 5% CO2 at 37°C. Culture
media was changed every three days. The cells were routinely passaged in tissue culture
flasks when they reached 80% confluence and were discarded after 20 passages to
ensure reproducibility of key characteristics.

2.2.3

Human platelet lysate

Human platelet lysate (PL) research grade was provided by PL BioScience (PL
BioScience GmbH). After thawing, 2U of heparin was added, PL was aliquoted in 1mL
Eppendorf tubes and stored at -80°C as recommended. Some aliquots were stored at 20°C to be used within two months. Before use, PL was thawed in the water bath.
Repeated freeze-thaw cycles were avoided to prevent precipitation.
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2.2.4

Gelatin methacryloyl (GelMA)

Gelatin methacryloyl (GelMA) was synthesized by a direct reaction of gelatin with
methacrylic anhydride. Gelatin (porcine skin, Type A, 300 Bloom, Sigma-Aldrich) was
dissolved in 10% w/v phosphate buffered saline (PBS), the solution was then autoclaved
using the liquid cycle. Sterilised gelatin solution was vigorously stirred at 37°C, while
methacrylic anhydride (0.6 mL/g gelatin) (MW=154.16, Sigma-Aldrich) was added. The
reaction was continued for 4 hours and terminated by centrifugation. Next, 5M sodium
hydroxide was added to the supernatant to adjust the pH 7. Chloroform was added to the
solution for sterilization purposes and the solution was dialyzed against deionized water
at 50°C for 4 days (cellulose membrane, molecular weight cut off (MWCO): 12kDa).
Lastly, the dialyzed GelMA solution was lyophilized and stored at -30°C until further
use. High degree of functionalization was verified by 1H nuclear magnetic resonance
(NMR) using a Bruker Avance III HD 400 MHz NMR spectrometer (Bruker BioSpin
Corp., Billerica, USA) (Figure 2.S1).

2.2.5

Bioink formulation

The HDF-PLGMA bioink was formulated as follow. HDF cells from passage 5 were
retrieved from liquid nitrogen and sub-cultured twice before being harvested with
trypsin and collected by centrifugation at 1200 rpm for 5 minutes. Cells were then
reconstituted in PLGMA bioink – based on a blend of 50% v/v PL, 15% w/v GelMA
dissolved in DMEM (supplemented with 10% v/v FBS, 1% v/v P/S) and 0.06% w/v
lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) – at a cell density of 1 × 106
cells/mL.
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The HDF-GelMA control bioink was formulated as follow. HDF were then
reconstituted in GelMA bioink –15% w/v GelMA dissolved in DMEM (supplemented
with 10% v/v FBS, 1% v/v P/S) and 0.06% w/v LAP – at a cell density of 1 × 106
cells/mL. All steps were performed within a sterile biosafety cabinet following good
laboratory guidelines to ensure sterility.

If not stated otherwise, experiments were performed with a PLGMA formulation
containing a blend of 50% v/v PL, 15% w/v GelMA and 0.06% w/v LAP, and GelMA
control formulation containing 15% w/v GelMA and 0.06% w/v LAP.

2.2.6

Fabrication of casted constructs

Constructs were casted by pipetting the ink formulation into custom-made moulds of
dimensions 8mm·5mm (D·H) and subjecting to UV light of 400 nm wavelength (λ) for
60 s (792 mJ). Immediately after crosslinking, constructs were placed in 12 well-plates
containing DMEM (10% v/v FBS, 1% v/v P/S) and cultured under 5% CO2 at 37°C.
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2.2.7

Fabrication of 3D bioprinted constructs

Figure 2.1 Bioplotter used for fabrication of biological relevant constructs.

A pneumatic extrusion-based 3D Bioplotter (Envision TEC, Gladbeck, Germany)
positioned inside a Class II biological safety cabinet was used to fabricate the 3D
printed PL-based (PLGMA) constructs. The 3D cuboid model was designed using CAD
software, exported as STL files, and sliced into layers using the Bioplotter RP®
software. The 3D constructs were then fabricated layer-by-layer in a dimension of 10
mm·10 mm·2 mm (W·L·H) with 0°/90° a crosshatch pattern, using disposable needle
tips of 200 µm, a slicing thickness 200 µm and strand spacing of 1.0 mm. For optimal
plotting of PLGMA constructs, the ink was allowed to reach the equilibrium
temperature (19°C) for 5-10minutes, the ink was then printed at a speed of 10 mm/s
under a pneumatic pressure of 2.6 bar onto a cooled platform (15°C). Right after
printing, constructs were moved to the crosslinking station where they were crosslinked
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under UV light of 400 nm wavelength (λ) for 60 seconds (792 mJ). Immediately after
crosslinking, constructs were placed in 12 well plates containing DMEM (10% v/v FBS,
1% v/v P/S). After all constructs were printed, well plates were placed in a double
container and transferred to a PC2 laboratory. Growth media was then changed in a
biosafety cabinet (BSC) utilising sterile instruments and wearing proper personal
protective equipment (PPE) and constructs were cultured under 5% CO2 at 37°C until
they were ready for experimentation.

2.2.8

Preliminary bioink characterization

The preliminary experiment to assess the printability of ink formulation was carried as
follow. Ink formulations were loaded into 1 mL disposable syringes and extruded
manually using constant force on microscope glass slides. Viscosity and extrudability of
different inks were determined from visual qualitative evaluation of single extruded
filaments images. The formulations were then compared according to those indicators,
and further rheological investigation was then carried with the ink formulation which
presented best behaviour in the qualitative printability evaluation.
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Figure 2.2 Schematic representation of the preliminary experiment used to measure the
ink printability.

2.2.9

Rheological characterization

Oscillatory and rotational rheological characterization were performed using an AR-G2
rheometer (TA Instruments) fitted with a stainless-steel cone-plate geometry (15 mm/
2°/ 55 μm). Pre-shear of 0.6 Pa was applied for 1 minute and the bioink was allowed to
reach the equilibrium temperature for 2 minutes prior to performing the experiments.
For each measurement, the cell-free bioink (PLGMA bioink, GelMA control and PL
control) was loaded in a liquid state onto the Peltier stage, tested only once and
discarded once investigated. Oscillatory temperature sweep from 35°C to 5°C at a rate
of 1.5°C/min, time sweep up to 10 minutes and stress sweep from 0.1 to 1000 were
carried out at a constant strain and frequency of 1% and 1Hz respectively. Strain sweep
from 0.01 to 1 was performed at fixed frequency of 1Hz and frequency sweep from 0.1
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to 100 Hz was performed at a fixed strain of 1%. The rotational steady state flow was
carried out at a shear rate (s-1) from 0.1 to 100 s-1 to analyse whereas the fluid's viscosity
decreases over time under shearing.

Figure 2.3 AR-G2 rheometer fitted with a stainless-steel cone-plate geometry
2.2.10 Shape fidelity

After printing, shape fidelity was assessed by qualitative screening of extruded
filaments from macroscopic images and by the printability index (Pr) according to
Ouyang et al. parameter.[162] Macroscopic images of PLGMA printed constructs were
processed using ImageJ software, which measured the perimeter and area of
interconnected channels (n > 20). The Pr value was then calculated to find the pore
perimeter normalized by pore area following this equation:
𝑃𝑟 = 𝐿2 ⁄16𝐴
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Eq. (1)

Where, L is perimeter and A is area. Pr = 1 indicates perfect extrusion line uniformity
and Pr > 1.1 had unacceptable uniformity.

2.2.11 Mechanical characterization

Figure 2.4 EZ-S mechanical tester.

The indentation test was carried out on an EZ-S mechanical tester (Shimadzu Co.) using
a cylindrical flat ended, stainless-steel indenter (990 μm in diameter) attached to a 10 N
load cell at a crosshead speed of 0.5 mm/min. The Young’s modulus of each cell-free
PLGMA construct was calculated through the slope of the applied force against
indentation depth (0-100 μm) plot following this equation:
𝐹 = 8 ⁄3 𝑎𝐸𝑑

Eq. (2)

Where, 𝐹 is the applied force (Newton), 𝑑 is the indentation depth (mm), and 𝑎 is the
radius of the indenter tip (0.495 mm). The slope of the linear fit was then used to
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calculate the hydrogel modulus (E). In each case, five cell-free specimens were tested,
and the average values were calculated.

2.2.12 Swelling behavior

The swelling behaviour of cell-free PLGMA casted constructs and GelMA control was
evaluated after incubation in solutions PBS solution pH 7.4 or pH 5 (to simulate
swelling behaviour in different stages of the healing process) at 37 °C for 24 h to reach
the swelling equilibrium. After removal from the swelling solution, the constructs were
gently blotted with Kimwipes to remove residual liquid, and the swollen weight of each
construct was recorded (Ws). The samples were subsequently lyophilized and weighed
again to determine the dry weight of each construct (Wd). The swelling ratio of the
swollen hydrogels was calculated according to equation (3). [124, 163]
𝑊𝑈 = (𝑊𝑆 − 𝑊𝐷)/𝑊𝐷

Eq. (3)

Three samples of each group were used to calculate the means and standard deviation.

2.2.13 Enzymatic degradation

Accelerated enzymatic degradation of cell-free PLGMA constructs and GelMA control
was performed as follows. After polymerization, casted constructs were placed in 24well plate and allowed to reach swelling equilibrium overnight at 37 ◦C. Following this,
constructs were gently blotted with Kimwipes to remove the residual liquid, and the
initial weight of each construct was recorded (W1). Constructs were then immersed in
the digest solution containing type I collagenase (Sigma-Aldrich) dissolved in PBS (pH
7.4) and incubated at 37 ◦C. [164] At specific time points, samples were removed from
the enzymatic solution, gently blotted, and the residual mass was of each construct was
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recorded (W2). The degree of degradation of each sample at specific time point was
calculated according to the following equation:
𝑅𝑒𝑠𝑖𝑑𝑢𝑎𝑙 𝑚𝑎𝑠𝑠(%) = 𝑊2/𝑊1 ∗ 100

Eq. (4)

Four samples of each group were used to calculate the mean and standard deviation.

2.2.14 Growth factor release

The in vitro release study of GFs from cell-free printed PLGMA were carried out in
PBS at 37 °C for up to 2 weeks. After UV crosslinking, the 3D printed constructs were
placed in a 24 well-plate containing 1 mL of PBS/well, which was changed to new PBS
prior to incubation to remove non-crosslinked material. Samples were then incubated at
37°C. At determinate time points (day 1, 3, 5, 7, 10 and 14), the supernatant was
collected and stored at -20 °C until further use. Total amount of GF in the PL raw
material and amounts of the released GFs from the PLGMA constructs were quantified
by Enzyme-Linked Immunosorbent Assay (ELISA) according to the manufacturer’s
protocol. PDGF-αβ and VEGF were quantified using respective DuoSet ELISA
development kit with DuoSet Ancillary Reagent Kit 2. PDGF-ββ, EGF, FGF and TGFβ1 were quantified using the Simple Step ELISA kit (ABCAM). Concentrations of GF
were calculated based on a standard curve generated using the standard run with that
assay. The optical density of the three replicates were used to calculate the means and
standard deviation. At day 14, constructs were enzymatically digested using 20 U of
collagenase I and the amounts of entrapped GFs were quantified by ELISA respectively.
The GF release profile was calculated according to the following equation:
(𝐺𝐹 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑)/(𝐺𝐹 𝑡𝑜𝑡𝑎𝑙) × 100%
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Eq. (5)

Where GFreleased is the amount of GF released at specific time point and GFtotal is the
sum of GF released plus GF remaining in the PLGMA construct.

2.2.15 HDF morphology, viability, and proliferation

Actin filaments from the HDF cytoskeleton were visualized by phalloidin staining
according to the manufacturer protocol (ThermoFisher Scientific). HDF-laden PLGMA
constructs and HDF-laden GelMA control were first fixed in 3.7% paraformaldehyde
for 30 minutes. Fixed samples were incubated in a blocking solution containing 5% v/v
donkey serum diluted in 0.3% v/v Triton X-100 at room temperature for 1 hour.
Samples were then stained with Alexa Fluor 488 phalloidin (5:200) in 5% v/v donkey
serum

for

1

hour

and

counterstained

with

4′,6-di-amidino-2-phenylindole

dihydrochloride (DAPI, 1 μg/mL) diluted in 5% v/v donkey serum for 10 minutes and
imaged using a confocal laser scanning microscope (Leica TSC SP5 II). Cell viability
was evaluated through LIVE/DEAD staining using calcein AM (5 μg/mL) / propidium
iodide (PI, 1 μg/mL) according to the manufacturer protocol. Images were acquired at
day 1, 7 and 14. ImageJ was used to quantify the number of total live and dead cells
within the samples (n = 10). The PrestoBlue assayTM was performed according to the
manufacturer’s protocol to measure the proliferation of HDFs encapsulated in the 3D
printed hydrogels. Cells were cultured up to 14 days and data was collected at day 1, 7
and 14. At these time points, samples were incubated with the PrestoBlue reagent, and
their optical density (OD) was measured at 544/590 nm using a microplate reader
(POLAR star Omega, BMG Labtech). Three independent samples of each group were
used to calculate the means and standard deviations.

2.2.16 Immunohistochemistry assay
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HDF-laden PLGMA constructs were first fixed in 3.7% w/v paraformaldehyde for 30
minutes. Fixed samples were incubated in a blocking solution containing 10% v/v
donkey serum in PBS diluted in 0.3% v/v Triton X-100 at room temperature for 1 hour.
Samples were then incubated with primary antibody appropriately diluted in antibody
dilution buffer, 10% v/v donkey serum in PBS, overnight at 4°C. Rinsed with 0.1% v/v
Triton X-100 in PBS for three changes. The primary antibodies used were rabbit
polyclonal anti-collagen I, rabbit polyclonal anti-collagen III, rabbit polyclonal antielastin. Samples were incubated with Alexa 488 anti-rabbit conjugated secondary
antibody at room temperature for 1 hour. Rinsed with 0.1% v/v Triton X-100 in PBS for
three changes. Lastly, samples were counterstained with DAPI at room temperature for
5 minutes, rinsed and mounted. The staining was then imaged by confocal laser
scanning microscopy (Leica TSC SP5 II, USA).

2.2.17 RNA isolation and RT-qPCR analysis

Real-Time PCR was used to quantify the gene expression of type I and type III
collagen, fibronectin and elastin, major components of the ECM synthesized by
fibroblasts. HDF-laden PLGMA constructs and HDF-laden GelMA control were first
mechanically broken using a tissue homogeniser. Total RNA was extracted from cells
using AurumTM Total RNA Mini Kit according to the manufacturer’s protocol. The
RNA isolated was then reverse transcribed into cDNA according to the manufacturer’s
protocol. After cDNA transcription, cDNA was quantified by Nanodrop and normalized
to 50 ng/mL. Real-time PCR was then performed using the SsoAdvancedTM Universal
SYBR® Green RT- PCR Kit. A list of primer sequence information is provided in Table
2.S1. All reactions were performed in triplicate. Relative gene expression represents
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data normalized to GAPDH and expressed relative to 2D HDFs. Data were analysed
according to the comparative threshold Cycle (∆∆Ct) method using the formula:
∆𝐶𝑡 = 𝐶𝑡 𝑡𝑎𝑟𝑔𝑒𝑡 – 𝐶𝑡 𝑛𝑜𝑟𝑚

Eq. (6)

∆∆𝐶𝑡 = ∆𝐶𝑡 𝑠𝑎𝑚𝑝𝑙𝑒 – ∆𝐶𝑡 𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑜𝑟

Eq. (7)

𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑔𝑒𝑛𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 2−∆∆𝐶𝑡

Eq. (8)

Firstly, ∆Ct is calculated by the difference between Ct values of the target and the
normalizer (housekeeping gene), subsequently, samples are normalized to the ∆Ct of a
control (2D HDFs culture), which is then used to find the relative expression of the gene
of interest using the expression 2-∆∆Ct. Means and standard deviation for each relative
gene expression were calculated.

2.2.18 Statistical analysis

One-way analysis of variance (ANOVA) test followed by Tukey's post-hoc test was
used to assess the statistical significance of results between groups. The statistical
analysis was performed with the software OriginPro at a confidence level of 95%.
Differences were considered statistically significant at p < 0.05. Data were expressed as
the mean ± standard deviation (SD) for n > 3.
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2.3

Results

2.3.1

Bioink formulation and characterization

Figure 2.5 Schematic representation of the bioprinting process from material
selection/ink formulation to shape fixation though UV light.
GelMa – gelatin methacryloyl, PL – platelet lysate, Skin cells – human dermal
fibroblasts. The fabrication process of the 3D printed multifunctional construct
consisting of platelet lysate (PL) and gelatin methacryloyl (GelMA) (PLGMA) is
illustrated in Figure 2.6 showing the pre-printing, printing, and post-printing stages.
This process enables encapsulation of cells and direct immobilization of GFs in the
PLGMA final 3D printed construct.

Table 2.1 Preliminary experiments on ink viscosity.
Thrombin

Ca

Gelatin

Gelma

Hydrogel

(U)

(mM)

(w/v)

(w/v)

characteristics

-

-

-

-

F

-

2

5

-

-

WG/F

50%

50%

2

5

-

-

WG/F

Ink 4

50%

50%

5

10

-

-

WG/F

Ink 5

50%

50%

10

20

-

-

WG/F

Ink 6

50%

50%

-

12

-

-

WG/F

Ink 7

50%

50%

-

24

-

-

WG/F

Ink 8

50%

50%

-

-

5%

-

F

Ink 9

75%

25%

-

-

5%

-

F

Ink 10

50%

50%

-

-

10%

-

G

Ink 11

75%

25%

-

-

10%

-

G

Ink 12

50%

50%

-

-

-

10%

G*

Ink 13

50%

50%

-

-

-

15%

G

PL

DMEM

Ink 1

100%

-

Ink 2

100%

Ink 3
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F: Fluid solution; WG/F: Weak gel while in the Eppendorf, but fluid once extruded. G: Gel-like solution.
G*= may need lower temperature to become gel.

A preliminary experiment was performed to assess the printability of various cell-free
bioink formulation. The results show that PL is crosslinked with thrombin and/or
calcium, however, the pressure applied during the extrusion process irreversibly disrupt
the fibrin network. Therefore, gelatin or GelMA was added to improve its extrudability.
A

B

Figure 2.6 Platelet lysate gel crosslinked with calcium and thrombin.
(A) The non-homogeneous PL crosslinked gel (B) lost its consistency once extruded.

PL-gelatin formulation containing 10% of gelatin allowed appropriate filament
deposition, however post-crosslinking with calcium and/or thrombin (Table 2.1) was not
strong enough to hold the structure after 10 min at 37oC. Gelatin methacryloyl (GelMa)
was then incorporated into the PL bioink, it not only allowed appropriate filament
deposition during extrusion but also enabled irreversible crosslinking through UV light.
Because of that, the formulation containing PL and GelMA (PLGMA) was chosen for
the following experiments.
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Figure 2.7 Oscillatory and rotational rheological behavior of PLGMA.
(A) Oscillatory temperature sweep from 35°C to 5°C showing modulus (Pa) as function
of temperature (°C). (B) Time sweep up to 10 minutes showing modulus (Pa) as
function of time. (C) Strain sweep from 0.01-1 showing modulus (Pa) as function of
strain. (D) Stress sweep from 0.1 to 1000 showing modulus (Pa) as function of stress.
(E) Frequency sweep from 1 to 100Hz showing modulus (Pa) as function of frequency.
(F) Rotational steady state flow showing viscosity as a function of shear rate (1/s).

Oscillatory and rotational rheological characterization (Figure 2.7) was performed with
the cell-free PLGMA bioink to obtain an accurate analysis of the bioink behaviour and
predict its printability. The PLGMA bioink sol-gel transition point was determined by a
temperature sweep from 35°C to 5°C, when the storage modulus (G′) surpassed the loss
modulus (G′′) around 25oC (Figure 2.7A). Therefore, subsequent experiments were
performed at 19oC (G′ > G′′). Time dependent rheological properties were demonstrated
by time sweep, showing G’ and G” modulus was relatively stable over 600s, suggesting
PLGMA does not undergo major structural rearrangement that would influence its
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rheological behaviour within the period of 600 s (Figure 2.7B). The strain amplitude
sweep (0.01 – 1) and stress sweep (0.1 – 1000) demonstrated the PLGMA possesses a
large linear viscoelastic region (LVR), suggesting consistency and stability of the bioink
even under higher deformations (Figure 2.7C&D). Frequency sweeps (0.1 – 100 Hz)
shows that the PLGMA bioink exhibited gel-like behaviour, as indicated by parallel G′
and G′′ modulus not influenced by this frequency range (Figure 2.7E). The rotational
steady-state flow shows the apparent viscosity of PLGMA decreases with increasing
shear rate, indicating the PLGMA bioink is a shear-thinning fluid also referred to as a
pseudoplastic fluid (Figure 2.7F).

Overall, the PLGMA bioink formulation demonstrated a significant improvement in
rheological performance in comparison to PL itself, yet similar behaviour in comparison
to GelMA, which enables extrudability and the capacity of forming self-supporting
layer. Based on the rheology data, a nozzle head temperature of 19oC was selected for
the fabrication of 3D printed PLGMA constructs to allow appropriate filament
deposition during extrusion and printing, and the platform was cooled down to 15 °C to
support shape fidelity. The printing pressure and speed was 2.6 bar and 10 mm s−1,
respectively.

70

Figure 2.8 Physical and mechanical characteristics of the PLGMA printed construct.
(A) Macroscopic view of the 3D printed lattice structure of the crosslinked PLGMA
construct demonstrating good printability resolution and shape fidelity. (B) Crosssectional SEM image of freeze-dried PLGMA construct at high magnifications showing
heterogeneous microporous structure. (C) Swelling behaviour of cell-free PLGMA
casted constructs after incubation in solutions solution pH 7.4 or pH 5. (D) Young’s
modulus of PLGMA construct as function of polymer concentration. (E) Accelerated
enzymatic degradation of cell-free PLGMA constructs. (*) significant difference (p <
0.05), (NS) no statistically significant difference (p ≥ 0.05).
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Figure 2.8A shows a typical macroscopic view of the 3D printed cell-laden lattice
structures using PLGMA, highlighting the successful stacking of multiple layers of
PLGMA bioink along the z-direction with good shape fidelity. Printability index (Pr) of
PLGMA constructs were found in the range of 0.9 - 1.1, demonstrating good shape
fidelity and mechanical stability. The 3D printed constructs are easy to handle with
retained structural integrity. Figure 2.8B illustrates the heterogeneous microporous
structure of the freeze-dried PLGMA cross-section at high magnifications.

In order to investigate the effect of the environmental pH on the swelling behaviour of
PLGMA constructs, swelling studies were performed by incubating PLGMA in PBS
buffer with different pH (pH 5 and 7.4). PLGMA swelling ratio at pH 5 (8.2% ± 0.3)
and pH 7.4 (8.6% ± 0.5) (Figure 2.8C). According to this data, PLGMA constructs
showed swelling capacity which was not significantly influenced by environmental pH.
Moreover, no significant difference between PLGMA and GelMA swelling behaviour
was found, showing that the incorporation of PL into the bioink did not significantly
change the mechanical properties of the PLGMA constructs when compared to the
GelMA control group.
Figure 2.8D shows the Young’s modulus of the cell-free PLGMA constructs (ranging
from 5.6 ± 0.4 KPa to 35 ± 1.4 KPa), which can be modulated by varying the GelMA
concentration (2.5%, 5%, 7.5% to 15% w/v). The PLGMA constructs were shown to be
more resistant to enzymatic degradation in comparison to the GelMA control group
(Figure 2.8E). PLGMA in PBS pH 7.4 without the presence of enzymes exhibited no
significant degradation. PLGMA samples under the accelerated degradation conditions
lost half of their mass at around 2.6 hours, while the GelMA control group lost half of
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its mass at around 1.2 hours. The experiment was carried out for 4 hours as GelMA
samples were extensively digested at that time point.

2.3.2

In vitro growth factor release

Figure 2.9 Growth factor release study from 3D printed cell-free PLGMA constructs.
(A)-(F) Cumulative release profile of PDGF-αβ, PDGF-ββ, VEGF, EGF, FGF and
TGF-β1 from the 3D printed PLGMA construct after 2 weeks of incubation. Mean ±
SD; n >4. These growth factors were used as an indicator of the multiple factors and
biologically relevant molecules released from 3D printed PLGMA.

Platelet lysate contains a large number of bioactive proteins, many of which have a
fundamental role in haemostasis and tissue remodelling.[131] In this study, PDGF-αβ
and -ββ, VEGF, EGF, FGF, and TGF were used as an indicator of the multiple factors
and biologically relevant molecules present in the PL. The total concentration of PDGFαβ and -ββ, VEGF, FGF, EGF and TGF-β1 in the PL used to fabricate PLGMA
constructs measured approximately 34 ng/mL, 17 ng/mL, 0.9 ng/mL, 0.03 ng/mL, 1.5
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ng/mL and 80 ng/mL, respectively. The overall encapsulation efficiency for each GF
was approximately 85%. After crosslinking, samples were washed in PBS to remove
non-crosslinked polymer and GFs, therefore non-crosslinked GFs lost in the first
instance were not considered in the calculation of release studies.

Figure 2.9 (A-F) shows the cumulative release profiles of PDGF-αβ (56% ± 6), PDGFββ (45% ± 1), VEGF (43% ± 2), EGF (42% ± 4), FGF (51% ± 5) and TGF-β1(43% ± 3)
from the 3D printed construct over a period of 2 weeks. The data indicates that after two
weeks of incubation, GFs were still not exhausted from the constructs, with an average
of 46% of the total GFs being released. This finding suggests this platform could be
used to retain and deliver GFs and other relevant molecules in a sustainable manner for
more than 2 weeks under cell-free, non-enzymatic conditions.

2.3.3

Biological characterization

The influence of the PLGMA matrix on the viability, proliferation, and morphology of
encapsulated HDFs was determined in vitro using printed HDF-laden PLGMA (HDFPLGMA) constructs. A preliminary experiment was conducted to establish the optimal
concentration of PL in the ink formulation for best biological performance towards
HDFs. Bioink formulations containing different concentrations of PL (10, 25, 50, 75,
100% v/v) with constant concentration of GelMA (15% w/v) and LAP (0.06% w/v) were
used to encapsulate HDFs (at a cell density of 1 × 106 cells/mL) (Figure 2.S2). All five
casted HDF-PLGMA groups (10, 25, 50, 75, 100% v/v) showed high cell viability (≥
96%) with no significant difference between groups (p > 0.05) in the first week of
culture. Moreover, casted HDF-PLGMA groups containing 100%, 75% and 50% of PL
also showed high proliferation rate (average of 2.5-fold increase following a week of
culture), 25% of PL showed proliferation rate around 1.7-fold increase following a week
of culture. Lastly, the group containing 10% of PL showed proliferation rate around 1.2fold increase following a week of culture. Based on this data, the ink formulation
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containing 50% PL was selected for the fabrication of 3D printed HDF-PLGMA
constructs.

Figure 2.10 Assessment of 3D printed HDF-laden PLGMA viability, attachment and
proliferation.
(A) Fluorescent Live/Dead staining images of 3D printed HDF-PLGMA construct at 3
time points. (B) Bright field image showing spatial arrangement and morphology of the
3D printed HDF-PLGMA cultured for 3 days. (C) Fluorescent images from actin
filaments visualized with phalloidin staining of 3D printed HDF-PLGMA. (D)
PrestoBlue assay showing fold change in cell proliferation of 3D printed HDF-PLGMA
(Print-PLGMA) in comparison to casted HDF-PLGMA (Cast-PLGMA), casted HDFGelMA control group (Cast-Ctrol) and printed HDF-GelMA control group (Print-Ctrol)
after 7 and 14 days of culture. Scale bars as indicated.
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2.3.4

ECM deposition by HDF

Printed and casted HDF-laden GelMA (HDF-GelMA) were used as a control since
GelMA hydrogels have been widely used in 3D cell culture. Live/dead confocal
imaging (Figure 2.10A) showed high viability (≥ 96%) of the 3D printed HDF-PLGMA
after 24 hours of encapsulation (Figure 2. S5), which was then maintained for over 2
weeks of culture. The printed HDF-GelMA control group also showed high viability (≥
93%). The cell distribution and morphology of the printed HDF-PLGMA after 3 days of
culture is also demonstrated through bright field microscope images in Figure 2.10B.
Moreover, high confluency of an elongated spindle-like shaped fibroblast subpopulation (printed HDF-PLGMA) after just a week of culture demonstrates the cells
were attaching and thriving well in the matrix. This was confirmed by F-actin staining
(Figure 2.10C), which showed the change in cell cytoskeleton by the assembly and
reorganization of actin filaments from a random orientated network of short filaments at
day 1 to long parallel actin filaments that were arranged into tight bundles extending
across the cell body from day 7 to 14. In accordance to these findings, a significantly
higher level of HDF proliferation is observed in the printed HDF-PLGMA (Figure
2.10D) in comparison to the casted HDF-PLGMA group, as well as to the casted and
printed HDF-GelMA control groups, with more than a 4-fold increase following one
week of culture and an 8-fold increase following two weeks of culture. The ECM is a
complex network consisting of structural proteins, collagens, laminins, elastin,
fibronectins, proteoglycans and hyaluronan arranged in a highly organised manner,
contributing to the strength and structural integrity of the tissue.[13] Here, some of the
key ECM components – collagen I, collagen III, fibronectin and elastin – synthesised by
fibroblasts during the wound healing process were studied to demonstrate the effect of
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GFs present in the PLGMA constructs in supporting the deposition of ECM by HDF.
Fluorescent immunohistochemistry staining and SYBR Green RT-PCR assay
demonstrated that the GFs in the PLGMA matrix were bioactive and stimulated ECM
protein

synthesis.

The

fluorescent

staining

images

(Figure

2.11A)

shows

immunohistochemical expression of fibrillar collagen type I and type III, elastin and
fibronectin markers deposited by printed HDF-PLGMA after 14 days of culture. All our
markers show organisation, especially collagen type I, which exhibited well defined
fibres oriented in parallel. Figure 2.11B shows a comparison of the relative
quantification of collagen type I and type III, elastin and fibronectin based on the
expression of these macromolecules in 3D printed HDF-PLGMA and HDF-GelMA
relative to 2D HDFs, normalised to the housekeeping gene GAPDH. Higher expression
of collagen I, collagen III, fibronectin and elastin were found in 3D printed HDFPLGMA in comparison with 3D printed HDF-GelMA control group, but only type I and
type III collagen showed significant differences. Briefly, GFs present in the PLGMA
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constructs showed a positive impact in the synthesis of ECM components by dermal
fibroblasts cultured for 2 weeks.

Figure 2.11 Assessment of ECM deposition by 3D printed HDF-PLGMA.
(A) Fluorescent images from immunohistochemical staining with polyclonal antibodies
against type I collagen, type III collagen, fibronectin and elastin of 3D printed HDFPLGMA constructs, respectively. Scale bars as indicated. (B) Relative gene expression
of collagen I, collagen III, fibronectin and elastin from printed HDF-PLGMA construct
in comparison with printed HDF-GelMA control group. Relative gene expression
represents data normalized to GAPDH and expressed relative to 2D HDFs. Mean ± SD;
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n >3. (*) significant difference (p < 0.05), (NS) no statistically significant difference (p
≥ 0.05).

Cell and ECM organisation have a direct influence in the tissue remodelling capacity
and healing potential. Random reorganisation of ECM during the healing process is
linked to impaired tissue regeneration and abnormal scarring, which can lead to severe
morbidity due to physical dysfunction and psychological stress.[13] Collagen type I,
collagen type III, elastin and fibronectin fibres from 3D printed HDF-PLGMA
constructs have shown a certain level of organization and alignment, which could have
followed the cell alignment, influenced by the bioink shear and extensional flows during
the extrusion process. Gene expression data further indicate the superior performance of
3D printed PLGMA in supporting the deposition of ECM components by the
encapsulated HDFs compared to the GelMA control group, likely due to the presence of
GFs and other relevant molecules in the PLGMA construct. Both GFs and the ECM
have a dynamic interaction which is essential to all phases of the healing process. This
interaction occurs in multiple ways and is bi-directional. The ECM regulates GF
signalling dependent on ECM-GF binding, correspondingly, GFs modulate ECM
deposition by stimulating cells to increase production of ECM components or regulating
production of matrix-degrading proteases and their inhibitors.[165] Further research will
enable better insight about the ECM and GF interaction and to answer if this particular
ECM alignment would better assist the remodelling process and enhance tissue
regeneration.
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2.4

Discussion

The development of an extrusion-based bioink formulation derived from PL is
described herein, which can be used to fabricate a 3D cell delivery system to
simultaneously release GFs in a sustainable manner, while providing a supportive
network that mimics the native ECM for skin cells to thrive. Ultimately, the PLGMA
bioink’s rheological behaviour was significantly improved in comparison to PL,
whereupon the PLGMA constructs enabled sustained release of the GFs that are
essential to wound healing, improved cell proliferation as well as ECM synthesis of the
co-printed HDFs.

An ideal bioink should meet specific rheological characteristics appropriate to the
printing method to be utilised. The printed structure should also provide optimal
mechanical, chemical, and biological characteristics to support adequate cell
networking, organization and function of the tissue.[166, 167] Platelet lysate is rich in
fibrinogen and, in contact with thrombin and/or calcium, naturally forms a polymeric
fibrin network.[168] This crosslinked fibrin network was previously shown to be
unsuitable for an extrusion-based printing process due to a lack of robustness in the
extruded structure.[169] Therefore, platelet derived products have been incorporated
with other biomaterials to formulate a composite bioink which meet specific rheological
characteristics appropriate to the printing method to be utilised. Faramarzi et al. [156]
reported an alginate-based bioink incorporated with platelet-rich plasma (PRP) for
application in musculo-skeletal and cardiovascular tissue engineering. Mendes et al.
[157] reported a bioink composed of platelet lysate hydrogels reinforced by cellulose
nanocrystals for development of xeno-free 3D tissue models.
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In this study, GelMA was added to improve the bioink extrusion performance. GelMA
is a denatured type of collagen that has been widely used as a versatile matrix for tissue
engineering scaffolds.[121-124] GelMA hydrogels exhibit remarkable tunable
mechanical, degradation and swelling properties, which makes them ideal candidates for
skin tissue engineering.[124] GelMA’s inherent thermo-responsive characteristics and
pseudoplastic behaviour facilitate filament deposition during the extrusion process and
reduce nozzle-clogging,[125] whilst protecting cells against excessive shear stress.[126]
Moreover, its photo-crosslinkable methacryloyl groups enable irreversible shape
fixation of the final printed construct.[127] LAP is a photoinitiator commonly used in
bioprinting and it was also added to the ink formulation at a final concentration of
0.06% w/v because several studies have reported that low LAP concentration enabled
high viability during direct encapsulation of cells.[170-172]

The study of the physico-mechanical properties of tissue engineered scaffolds is crucial
to better mimic native tissue, thereby strengthening cell attachment and proliferation to
achieve complete wound repair.[160] Figure 3A shows the macroscopic final 3D printed
PLGMA construct demonstrating that the optimised formulation provided desirable
extrudability, printing accuracy and shape fidelity. The stacking of multiple layers of
PLGMA bioink was also demonstrated to show this system could be potentially used to
fabricate a skin equivalent for various wound depth. The mechanical property of the
PLGMA constructs are readily tuned to mirror the broad range of elasticity found in
native skin (104 - 106 Pa).[173-176] For this project, PLGMA containing 15% w/v
GelMA was chosen to fabricate fibroblast-laden constructs because its mechanical
properties are equivalent to the skin dermal layer[177] (~35 KPa).
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Here, accelerated enzymatic degradation assay was performed to investigate the
differences in degradation profile of PLGMA and GelMA. Lima et al. previously
described the incorporation of platelet lysate increased the resistance of collagen gel
beads towards collagenase degradation. [178] In accordance with this report, our data
revealed PLGMA constructs exhibited improved resistance to enzymatic breakdown in
comparison to GelMA constructs. This improvement in stability could be attributed to
the reinforcement of the GelMA structure by a fibrin mesh. An ideal biocompatible and
biodegradable platform for wound healing application needs to follow the dynamics of
the wound repair matching its degradability rate to the timeline of the healing process.
Therefore, although improved stability was demonstrated in vitro, further investigation
is needed to confirm PLGMA stability in vivo and its suitability as a skin tissue
engineering substitute.

Upon injury, skin get exposed to internal fluids which have physiological pH (7.4) and
the slightly acidic environment (pH 4–6) of a healthy skin then change to a more basic
one (6.5–8.5).[179] Therefore, swelling studies were performed at pH 5 and 7.4 to
model change in the pH of the wound environment. High water uptake ability is a
desirable characteristic of a biosynthetic skin substitute. The ability to maintain a moist
environment and adsorb wound exudate has been reported to promote fibroblast
proliferation and keratinocyte migration, which is important for complete regeneration
of the wound.[180] Hydrogel-based dressings, due to their water-soluble nature, have
several reported advantages including maintaining optimal moist conditions, permeating
oxygen, clearing debris, as well as protecting the wound from infection and
contamination. [179] PLGMA constructs, which are a hydrogel-based system, were
shown to have a good affinity toward the aqueous media and their swelling capability
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was not significantly affected by the range of pH tested. Wound infection may influence
the wound pH and result in delayed and even impaired healing. Platelet derived
products have been reported to have antimicrobial properties against several pathogens
commonly associated with wound infections [181, 182] Therefore, further studies
demonstrating antimicrobial activity of PLGMA constructs against common airborne
bacteria as well as in vivo swelling and degradation studies will also be performed

Human-recombinant GFs are available in a purified form; however, tissue regeneration
cannot be effectively triggered by a single agent.[71] The additive and/or synergistic
effect of a combination of GFs on the proliferation, migration and differentiation of
various cell types both in vitro and in vivo, has been reported to lead to enhanced
healing efficacy.[183] The use of multiple recombinant factors as therapeutic agents, on
the other hand, has been hindered by their safety, high production cost, low stability and
short half-life. For instance, FGF-1 has been shown to have low stability, with a short
active half-life of 1h in serum at 37 °C, whereas the half-life of bFGF is 3 minutes and
that of VEGF is about 50 minutes following intravenous injection.[184]

Platelet lysate is a suitable, abundant and cost-effective source of GFs.[185] The
commercial PL used in this work was manufactured from platelet units obtained from
healthy blood donors at European Medicines Agency (EMA)-licensed blood centres to
minimize batch-to-batch variation, nevertheless PL can be obtained from an autologous
source and implemented in a customisable and personalised approach.[131] We studied
the cumulative release of PDGF, VEGF, FGF, EGF and TGF-β1 from 3D printed
PLGMA over a 2-week period. The in vitro study confirmed that about 50% of the
payload was released for each GF from the PLGMA construct after 14 days in cell-free
conditions (without enzymatic degradation). The retention of growth factors in PLGMA
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constructs was greater than that reported for a fibrin-based scaffold loaded with platelet
lysate[186] or hydroxybutyl chitosan hydrogels loaded with platelet lysate growth
factors.[186] Since PL was directly incorporated into the bioink formulation without
any further modification, the retention of growth factors and other molecules could be
potentially attributed to the mechanical and physical properties of the polymer in the
bioink, and electrostatic interactions between growth factors and matrix.[187]

The effectiveness of GF therapy for regenerative medicine applications is largely
dependent on preserving bioactivity during fabrication and application.[188] Therefore,
the bioactivity of the GFs from 3D printed PLGMA construct were assessed in vitro
using human dermal fibroblasts, the predominant cell line of the cutaneous dermal layer.
In conventional tissue engineering approaches, cells are seeded into a cellular scaffold,
which makes it difficult to control their spatial distribution throughout the matrix.[160]

Bioprinting allows spatially controlled distribution of biomaterials, biological molecules
and living cells to generate complex 3D microenvironments. In addition, this technique
also enables more flexibility with the design and introduction of macropores to the final
construct.[189] Figure 2.10A and B show that by encapsulating HDF into the bioink
formulation, it was possible to obtain a homogeneous distribution of cells throughout
the printed matrix. Since the proposed platform should deliver fibroblasts and GFs,
while supporting and guiding cell ingrowth, in vitro cytocompatibility against
fibroblasts was demonstrated as well as the potential to be used as a 3D cell culture
substrate for cell expansion, and ECM formation.

The stimulating effects of PL growth factors on cell growth and on the synthesis of
ECM has been previously demonstrated in a 2D setting using pancreatic stellate cells
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(PSC),[190] and more recently in a 3D printed setting using human adipose-derived
stem cells (hASCs).[157] In accordance to these reports, immobilized GFs from the
PLGMA constructs also promoted high cytocompatibility towards fibroblasts,
supporting enhanced cell viability, adhesion, metabolic activity and stimulating the
synthesis of new ECM by fibroblast. The improved proliferation of the 3D printed
HDF-PLGMA compared to the ones in cast PLGMA could be attributed to its lattice
structure. The increased interfacial surface area of the printed construct facilitates the
diffusion of nutrients and exchange of gases,[191] improving cell proliferation and
migration to the surface of the printed strands. Taken together, these data suggest that
PLGMA bioink provides a strong foundation for the fabrication of multifunctional
platform for wound management and tissue regeneration. Nevertheless, further
investigation in vitro and in vivo are needed to determine the effectiveness of the system
to co-deliver fibroblasts and GFs to the wound site, while protecting cells from acute
inflammatory environments and GFs from excessive enzymatic degradation as well as
its potential to guide the new tissue formation. Future studies will also involve the
incorporation of other relevant cells for skin tissue regeneration.

Fibroblasts provides the physical integrity of connective tissue by producing and
remodelling ECM components. During the healing process, fibroblast secrete structural
ECM components, such as elastin, procollagen, proteoglycans, and hyaluronic acid
(HA), involved in the formation of granulation tissue. The granulation tissue enables
infiltration of inflammatory cells to the wound site and ingrowth of new blood vessels
for nutrition and oxygen of the newly formed tissue. Fibronectin regulates the
neovascularization of granulation tissue and mediates collagen I/III fibrillar network
formation. Collagens are the main structural component of the ECM. [13] Collagen type
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I and III are the dominant type of collagen in cutaneous wound repair. Collagen I/III
proportion varies throughout different depths of the dermis and different stages of the
healing process. [12] During the early stages of the granulation tissue formation,
fibroblasts secrete primarily collagen type III leading to an increased expression of
collagen type III compared to type I, the ratio decreases again to normal levels in late
stages of the healing process. Abnormal changes of its normal expression is implicated
in fibrosis or hypertrophic scarring.[13] Moreover, type III collagen has been reported
to play a prominent role in cutaneous wound repair modulating scar tissue formation
and preventing impaired healing.[192] Our data revealed the remarkable capacity of
fibroblast cultured into PLGMA constructs to deposit ECM molecules. Additionally,
higher expression of collagen type III than collagen I by HDF-PLGMA demonstrated
the potential to emulate early stages of granulation tissue formation and provide support
for future investigation of capacity of the HDF-PLGMA platform to improve tissue
regeneration.

Cell and ECM organisation have a direct influence in the tissue remodelling capacity
and healing potential. Random reorganisation of ECM during the healing process is
linked to impaired tissue regeneration and abnormal scarring, which can lead to severe
morbidity due to physical dysfunction and psychological stress.[13] Collagen type I,
collagen type III, elastin and fibronectin fibres from 3D printed HDF-PLGMA
constructs have shown a certain level of organization and alignment, which could have
followed the cell alignment, influenced by the bioink shear and extensional flows during
the extrusion process. Gene expression data further indicate the superior performance of
3D printed PLGMA in supporting the deposition of ECM components by the
encapsulated HDFs compared to the GelMA control group, likely due to the presence of
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GFs and other relevant molecules in the PLGMA construct. Both GFs and the ECM
have a dynamic interaction which is essential to all phases of the healing process. This
interaction occurs in multiple ways and is bi-directional. The ECM regulates GF
signalling dependent on ECM-GF binding, correspondingly, GFs modulate ECM
deposition by stimulating cells to increase production of ECM components or regulating
production of matrix-degrading proteases and their inhibitors.[165] Further research will
enable better insight about the ECM and GF interaction and to answer if this particular
ECM alignment would better assist the remodelling process and enhance tissue
regeneration.
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2.5

Conclusion

Platelet lysate (PL) is an attractive source of GFs that play an important role
orchestrating the healing cascade. Despite GFs inherent potential for regenerative
medicine, the paucity of efficient delivery systems limits their use in the clinic. Herein,
we have established a composite PL and GelMA bioink formulation (PLGMA) for the
fabrication of multifunctional skin equivalent platforms, which shows promise in
several aspects of skin tissue engineering, including high cytocompatibility towards
HDF, as well as promoting cell attachment and proliferation. Further benefits of this
system include increased synthesis and deposition of ECM molecules. By combining
bioprinting technology with ‘smart’ functional bioinks, it is possible to offer superior
customizable solutions for patients with complex wounds in the future, overcoming
various limitations faced in tissue engineering and regenerative medicine. Although
more in-depth assessment to proof the proposed PLGMA platform therapeutical
efficacy in supporting skin tissue regeneration are currently underway, the present work
aimed to establish a foundation towards the development of a more complex skin
equivalent with complete functional performance.
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Supporting Information

Figure 2.S 11H NMR spectra of GelMA and unmodified Gelatin.
The lysine methylene peak (2.8 – 3.0 ppm) (b) was used to confirm the methacrylation
degree as lysine is the bonding site for methacryloyl conjugation, while the
phenylalanine peak (7.3 – 7.5 ppm) (a) was used to normalize the intensity of the lysine
peak. Therefore, the degree of functionalization was calculated by comparing the proton
signal (2.8 – 3.0 ppm) of unmodified gelatin (red) and GelMA (blue spectra).

Table 2.S 1List of primers used for real time RT-PCR
Gene

Primer sequence (5’-3’)

GAPDH

F: ATGGAAATCCCATCACCATCTT
R: CGCCCCACTTGATTTTGG
F: GGGAACGCGTGTCAATCC
R: CAGTTACACAAGGAACAGAACAGTCTCT
F: TGGTCAGTCCTATGCGGATAGA
R: CGGATCCTGAGTCACAGACACA
F: TCGCCATCAGTAGAAGGTAGCA
R: TGTTATACTGAACACCAGGTTGCAA
F: CTAAATACGGTGCTGCTGGC
R: CATGGGATGGGGTTACAAAG

Collagen I
Collagen III
Fibronectin
Elastin
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A

B

Figure 2.S 2 Preliminary assessment of viability and proliferation of HDF-PLGMA
formulated with different concentrations of PL.
(A) Fluorescent Live/Dead staining images of HDF-PLGMA constructs at day 1 and
day 7 of culture. Scale bars as indicated (100μm). (B) PrestoBlue assay showing fold
change in cell proliferation of casted HDF-PLGMA containing different PL
concentration cultured for a week.
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Figure 2.S 3 Preliminary assessment of proliferation – printed and casted PLGMA.
PrestoBlue assay showing proliferation of HDF encapsulated in three experimental
groups: casted PLGMA, printed PLGMA and GelMA control after cultured for up to
two weeks. Data was collected at 3 time points (day 1, 7 and 14) and read at
fluorescence intensity at 544/590nm. The rich microenvironment of the PLGMA casted
and printed groups promoted significantly higher proliferation in comparison to the
GelMa control group. Moreover, the porous 3D printed PLGMA structure leaded to the
highest cell proliferation among the groups tested.
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Day 7

Day 14

Casted

Printed

Day 1

Day 7

Day 1

Day 14

Printed

Day 1

LIVE/DEAD

LIVE/DEAD

LIVE/DEAD

Casted

LIVE/DEAD

HUMAN DERMAL FIBROBLASTS
Figure 2.S 4 Preliminary assessment of viability - printed and casted PLGMA.
Fluorescent Live/Dead staining images shows viability of HDF encapsulated into
printed and casted PLGMA constructs after cultured for up to two weeks. Images were
acquired using laser confocal fluorescence microscopy (Leica TSC SP5 II). Color-coded
depth images show the distribution of HDF in a 3D space (purple 0μm to pink 248μm)
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Day 0

Live / Dead

Figure 2.S 5 Live/Dead staining images of 3D printed HDF-PLGMA construct at day 0
(3 hours after printing). Scale bars as indicated (200μm).

Figure 2.S 6 Images of the negative controls from the immunohistochemical staining
of polyclonal antibodies against type I collagen, type III collagen, fibronectin and
elastin of 3D printed HDF-PLGMA constructs. Figure shows only DAPI staining. Scale
bars as indicated (50μm).
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3.1

Introduction

Bioprinting technology has been emerging as a fabrication tool for the development of
complex compartmentalized structures to support skin tissue regeneration.

The

selection of an appropriate combination of cells, alongside the selection of suitable
extracellular functional biomaterials for skin tissue printing plays a critical role in the
success of the final construct. Several cells (individually encapsulated in the matrix or
as cell aggregates) from autologous or allogenic nature have been exploited for skin
bioprinting. A simplified approach is often used to produce skin equivalents which
includes only dermal fibroblasts and/or epidermal keratinocytes without recreation of
skin appendices. The most exploited cells for fabrication of the dermal and epidermal
compartments of 3D skin constructs are fibroblasts and keratinocytes, respectively.[58,
91, 94, 95, 97, 106, 107, 114-117] Cubo et al., for example, used an extrusion-based
bioprinting system to develop a bilayer skin construct composed of plasma-derived
fibrin matrix populated with fibroblasts, topped by seeded keratinocytes. The bioprinted
skin-like structure could emulate specific skin structure/functions in terms of epidermal
terminal differentiation in vitro and in vivo.[101]

The skin is also a densely innervated organ. Upon skin injury, skin nerves may also get
damaged and if nerve regeneration is imperfect, it can lead to abnormal sensations,
chronic pain, or even permanent sensory deficits. Therefore, restauration of not only the
aesthetic aspect but also the skin sensation and perceptions could have a major impact in
a patient’s quality of life.[193] Delayed wound healing of denervated tissue further
highlight the importance of cutaneous nerves during the healing response. For example,
peripheral neuropathy is one of the possible causes of delayed wound healing in
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diabetes.[193] Electrical stimulation was proposed to improve nerve[194] and wound
healing,[195] however, its therapeutic setting is still limited.

Tissue-engineered skin alternatives combining relevant cells, biomolecules, and
biomaterials have been extensively used to establish a functional nerve network and
induce tissue regeneration.[196] Choi et al., for example, used a coaxial nozzle printing
to mimic the muscle structure, by fabricating a pre-vascularized muscle model with
human umbilical vein endothelial cells (HUVECs) and vascular decellularized ECM
(vdECM) in the outer shell and human muscle cells and skeletal muscle decellularized
ECM (mdECM) in the inner core. The coaxial nozzle printed structure demonstrated to
improve muscle fiber formation, vascularization, and innervation as well as 85% of
functional recovery in volumetric muscle loss injuries.[197]

Despite recent advances in the biofabrication field, the incorporation of skin cells
together with nerve cells into 3D printed constructs to generate an innervated skin-like
macrostructure that mimic physiological functions of the skin has yet to be explored.
Therefore, the aim of this work was to fabricate a more complex skin equivalent using
the platform (HDF-PLGMA) established in the previous chapter as a base. First, a
dermal-epidermal compartment was fabricated by seeding immortalized human
keratinocytes (HaCaT) in an HDF-PLGMA printed structure and initial characterisation
of the HaCaT/HDF-PLGMA construct was carried by expression of general
keratinocyte differentiation markers, and histological analysis. Then, to fabricate an
innervated dermal compartment, embryonic stem cell (ESC)-derived human NSCs
(hNSC-H9) neurospheres were incorporated in the HDF-PLGMA printed construct and
initial characterisation was performed to assess the ability of the HDF-PLGMA
platform to support neurite outgrowth and neuron maturation.
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3.2

Experimental Section

3.2.1

Materials

Key materials used in this chapter are introduced in detail as follow.

Materials

Source

Human dermal fibroblasts (HDF)

Cell Applications

Cat Number

Immortalized human keratinocytes (HaCaT)
human embryonic stem cell (hESC), WA09

WiCell

DMEM, high glucose, HEPES

Sigma-Aldrich

D1152

Fetal Bovine Serum

Interpath

SFBSN2

Penicillin/Streptomycin

Gibco

15140122

Ham’s F12

Life Technologies

21041025

Hydrocortisone

Sigma-Aldrich

Triiodothyronine

Sigma-Aldrich

Human transferrin

Sigma-Aldrich

Insulin

Sigma-Aldrich

Cholera toxin

Sigma-Aldrich

Ascorbic acid

Sigma-Aldrich

Epidermal Growth Factor (EGF-1)

Lonza

Neural media
Y27
Brain-derived neurotrophic factor (BDNF)
Nerve growth factor (B-NGF)
Neurotrophin-3 (NT-3)
Glial cell line-derived neurotrophic factor (GDNF)
Human platelet lysate (PL)

PL BioScience

Heparin

Sigma-Aldrich

Gelatin (porcine skin, Type A, 300 Bloom)

Sigma-Aldrich

Methacrylic anhydride

Sigma-Aldrich

P5927

Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP)

Sigma-Aldrich

900889

Rabbit polyclonal anti-cytokeratin 10

ABCAM

ab111447

Rabbit polyclonal anti-involucrin

ABCAM

ab53112

Rabbit polyclonal anti-collagen III

ABCAM

ab7778

Rabbit polyclonal anti-collagen IV

ABCAM

ab235296

H3149
G2500

Antibodies
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Rabbit polyclonal anti-cytokeratin

ABCAM

ab111447

Mouse monoclonal anti-Ki67(SOlA15) efluor 570

Life Technologies

41-5698-82

Chicken polyclonal anti-β tubulin III

Merk Millipore

AB9354

Goat polyclonal anti-trkA

R&D Systems

AF175

Mouse anti-trKB

R&D Systems

NOVNBP14789

Rabbit monoclonal anti-trKC

Invitrogen

7H3L20

Mouse monoclonal anti-MAP2

Sigma-Aldrich

M4403

Mouse monoclonal anti-BRN3A

Merk Millipore

MAB1585

Rabbit polyclonal anti-collagen I

ab21286

ABCAM

Invitrogen

D1306

AurumTM Total RNA 96 Kit

Bio-rad

7326800

iScript RT Supermix, 100 rxns

Bio-rad

1708841

SYBR® Select Master Mix

Life Technologies

4472897

Weigert’s Iron Hematoxylin Solution

Sigma-Aldrich

HT1079

Bouin’s solution

Sigma-Aldrich

HT10132

Biebrich Scarlet-Acid Fucshin solution

Sigma-Aldrich

HT151

Phosphotungstic Acid Solution

Sigma-Aldrich

HT152

Phosphomolybdic Acid Solution

Sigma-Aldrich

HT153

Aniline Blue Solution

Sigma-Aldrich

HT154

S-100B

Mouse anti-neurofilament 200
DAPI
PCR

Trichrome Masson

3.2.2

Cell culture

Human dermal fibroblasts (HDFs) were cultured as previously described on chapter 2.

Immortalized human keratinocytes (HaCaT) were cultured in growth media comprising
DMEM/Ham’s F12 (1:1) supplemented with 10% v/v FBS and 1% v/v P/S under
standard culture conditions in a humidified atmosphere with 5% CO2 at 37°C.
Differentiation media for HaCaT comprises of DMEM/Ham’s F12 (1:1) supplemented
with 10% v/v FBS and 1% v/v P/S, 0.4 μg/mL hydrocortisone, 5μg/mL triiodothyronine,
5 μg/mL human transferrin, 5 μg/mL insulin, 10 ng/mL cholera toxin, 10 ng/mL EGF-1
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and 50 μg/mL ascorbic acid. Culture media was changed every three days. The cells
were routinely passaged in tissue culture flasks when they reached 80% confluence and
were discarded after 20 passages to ensure reproducibility of key characteristics.

Embryonic stem cell (ESC)-derived human NSCs (hNSC H9) neurospheres used in this
work were kindly provided by S. Miellet and A/P M. Dottori, Illawarra Health and
Medical Research Institute, University of Wollongong (Human Ethics committee
approval #2017 375). hNSC H9 neurospheres are 3D aggregates of neural progenitors
produced by conventional neuronal generation protocol. Briefly, undifferentiated human
embryonic stem cell (hESC), WA09 (H9, WiCell), were maintained in feeder-free
conditions on a laminin (LAM) coated dish (Corning) using E8 basal medium (Life
Technologies). For neural induction, Neurobasal™ Medium (NB) (Life Technologies),
freshly supplemented with 10 µM SB431524 (SB) and 3 µM CHIR99021 was added
and maintained for five days. The media was changed every third day. Neural
progenitor cells were then pelleted in a 50 mL tube at 200 g for 3 minutes. Cells were
resuspended in NB medium supplemented with 10 ng/mL BMP-2 and 20 ng/mL FGF2.
Cells were plated in U-bottom ultra-low attachment 96-multiwell plates (Corning),
plates are spun at 200 g for 4 minutes. On the third day, media is top up with 50 µL of
freshly supplemented media. For neuronal differentiation, whole spheres are manually
disaggregated and plated onto PDL/LAM coated 24 well plate. Neural media is freshly
supplemented with 10 µg/mL of small molecule Y27 and 10 ng/mL brain-derived
neurotrophic factor (BDNF), nerve growth factor (B-NGF), neurotrophin-3 (NT-3) and
glial cell line-derived neurotrophic factor (GDNF), changing media every third day.
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3.2.3

Fabrication of epidermal-dermal constructs

Figure 3.1 Schematic representation of the HaCaT/HDF-PLGMA fabrication.
Showing the HDF-PLGMA bioprinting process from material selection/ink formulation,
printing and shape fixation though UV light, then the HaCat seeding and culture.

Bilayer models (HaCaT/HDF-PLGMA) were fabricated by pneumatic extrusion
printing (Envision TEC) the dermal component (HDF-laden PLGMA) and epidermal
component (keratinocytes HaCaT) was seeded on the top of the 3D printed HDF-laden
PLGMA construct (Figure 3.1). Briefly, three layers of HDF-PLGMA were printed as
previously described (0°/90° a crosshatch pattern, slicing thickness 200 µm and strand
spacing of 1.0 mm), then the fourth layer was printed at spacing of 0.4 mm. After
crosslinking, HDF-laden PLGMA was placed in 12 well plates containing HDF growth
medium and cultured for a week under standard culture conditions 5% CO2 at 37°C.
Samples were then transferred to a permeable membrane of a cell culture insert (airliquid interface setting - ALI), which can be air-lifted so the apical surface is exposed to
air, whereas the basal surface of the construct is in contact with the cell culture medium.
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Keratinocytes HaCaT (about 2 × 105 cells/cm2 density) were then seeded on top of
HDF-PLGMA and cultured submerged in HaCaT growth medium for a week to reach
confluency. Then, the construct was subjected to air exposure and cultured in
differentiation media under 5% CO2 at 37°C. Culture media was changed every day
after air exposure as media volume was low and cell density was high. HaCaT/HDFPLGMA samples were collected at specific time points for the following experiments.

3.2.4

Fabrication of innervated-dermal constructs

Figure 3.2 Schematic representation of the H9/HDF-PLGMA fabrication.
Showing the HDF-PLGMA bioprinting process from material selection/ink formulation
to shape fixation though UV light induced crosslinking, then the hNSC H9 sphere
seeding and culture.

Innervated dermal model (H9/HDF-PLGMA) were fabricated by printing (Envision
TEC) the dermal component (HDF-laden PLGMA) and then seeding the nerve
compartment (two weeks old hNSC H9 neurospheres of ~200µm diameter) on 3D
printed HDF-laden PLGMA (Figure 3.2). Briefly, HDF-PLGMA was bioprinted, as
previously reported in chapter 2, cultured in DMEM (10% v/v FBS, 1% v/v P/S) under
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5% CO2 at 37°C. Then, two weeks old hNSC H9 spheres were seeded on top of the
printed dermal construct, construct was flipped so hNSC H9 spheres would be on the
bottom. Co-cultured was maintained in supplemented neural differentiation media under
5% CO2 at 37°C, and collected for analysis at specific time points. H9/HDF-PLGMA
represents printed HDF-PLGMA and seeded H9.

3.2.5

Immunohistochemistry assay – keratinocyte differentiation

As previously reported, immunohistochemical analysis as performed as follow samples
were collected at specific time points, fixed in 3.7% v/v paraformaldehyde (PFA)
solution for 30 minutes, kept at 5°C or embedded in optimal cutting temperature (OCT)
compound, snap-frozen using dry ice and stored at -20°C. OCT embedded samples
blocks were cryo-sectioned into 10 - 20μm sections and mounted on glass slides. The
unspecific binding of the antibody was blocked by 5% donkey serum in PBS for 1 hour
at room temperature followed by overnight incubation with primary antibodies diluted
in blocking solution.

The expression of proteins associated with keratinocyte proliferation and differentiation
was analysed in 3D culture of HaCaT in 3D printed HDF-PLGMA constructs. The
primary antibodies used were rabbit polyclonal anti-cytokeratin 10, mouse monoclonal
anti-Ki67 (SOlA15) efluor 570, rabbit polyclonal anti-involucrin. ECM component was
analysed using goat polyclonal anti-collagen IV, and rabbit polyclonal anti-collagen III.
After 3 washes with PBS, the respective secondary antibodies were applied in blocking
solution for 1 h at room temperature, rinsed in PBS for 3 changes. Lastly, cell nuclei
were counterstained with DAPI, substrate solution at room temperature for 5 minutes,
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rinsed and mounted. The staining was then observed and imaged using confocal
microscope (Leica TSC SP5 II).

3.2.6

Immunohistochemistry assay – neuronal differentiation

The expression of proteins associated with neuronal proliferation and differentiation
was analysed in hNSC H9 neurospheres cultured in 3D printed HDF-PLGMA
constructs. Immunohistochemical analysis as performed as previously described. The
primary antibodies used were chicken anti-β tubulin III, S-100B, tropomyosin receptor
kinase (Trk): goat anti-TrkA, mouse anti-TrKB and rabbit anti-TrKC, mouse antiMAP2, mouse anti-BRN3A and mouse anti-neurofilament 200. ECM component was
stained using rabbit anti-collagen I. Cell nuclei were counterstained with DAPI,
substrate solution at room temperature for 5 minutes, rinsed and mounted. The staining
was then observed and imaged using confocal microscope.

3.2.7

RNA isolation and RT-qPCR analysis

As previously reported, total RNA was extracted from cells using AurumTM Total RNA
Mini Kit following the supplier’s instructions. Reverse transcription to convert RNA
sequence into cDNA was performed according to the manufacturer’s protocol using
C1000 TouchTM Thermal Cycler. The resultant cDNA was then subjected to qRT-PCR
using CFX96 Real-Time System (Applied Biosystems) with SsoAdvanced Universal
SYBR Green RT- PCR Kit according to the manufacturer’s protocol. All reactions were
performed in triplicate. Corresponding gene expression levels were normalized to
GAPDH. The fold-change of the target genes was calculated by using the 2−ΔΔCT method
as previously reported.

110

Table 3.1 List of primers used for real time RT-PCR
Gene

Primer sequence (5’-3’)

GAPDH

F: ATGGAAATCCCATCACCATCTT
R: CGCCCCACTTGATTTTGG
F: CTTCTGTCGAACACAGTGGTACCT
R: TCATCTCTTGGGTCCCTTTTACTT
F: CAGATGTGGACCATGCCATTGAG
R: CATCAATGTCATCCTGAGCTAGC

KGF-1
MMP-1

3.2.8

Masson trichrome staining

Histological analysis was performed to confirm the stratification for the epidermal layer
in the 3D culture of HaCaT in 3D printed HDF-PLGMA constructs. Masson trichrome
staining was performed according to the manufacturer’s protocol. Briefly, frozen
sections were mordanted in preheated Bouin’s solution at 56°C for 15 minutes, rinsed in
running tap water, treated with Weigert’s iron Hematoxylin solution for 5 minutes.
After removing the Hematoxylin solution, the sections were treated with Biebrich
Scarlet-acid Fucshin for 5 minutes. After rinsed with distilled water, slides were treated
with working phosphotungsten/phosphomolybdic acid solution for 5 minutes.
Subsequently, slides were treated with aniline blue solution for 5 minutes and, acetic
acid, 1%, for 2 minutes. Finally, the sections were rinsed with distilled water,
dehydrated, mounted, and observed.

3.2.9

CellTiter-Glo® 3D viability assay

CellTiter-Glo® 3D cell viability assay was used to determine the viability of hNSC H9
neurospheres encapsulated in crosslinked bioinks (cell-free PLGMA), according to the
manufacturer’s protocol. Samples were prepared by embedding H9 cells (spheres and
single cells) in 30 μL of bioink and crosslinking directly into opaque-walled multi-well
plates for 45 seconds (13.2mW). Samples were cultured under 5% CO2 at 37°C; culture
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media was added to each well and changed every other day. After four days of culture,
CellTiter-Glo® 3D reagent was added to each well, mixed for 5 minutes and allowed to
incubate for 25 minutes. Lastly, luminescent was recorded using a microplate reader
(POLAR star Omega, BMG Labtech).

3.2.10 Statistical analysis

One-way analysis of variance (ANOVA) test followed by Tukey's post-hoc test was
used to assess the statistical significance of results between groups. The statistical
analysis was performed with the software OriginPro at a confidence level of 95%.
Differences were considered statistically significant at p < 0.05. Data are expressed as
the mean ± standard deviation (SD) for n > 3.
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3.3
3.3.1

Results
HDF-PLGMA influence on HaCaT

Figure 3.3 Preliminary assessment of HaCaT differentiation and proliferation in 3D
printed HDF-PLGMA constructs.
HaCaT/HDF(1)-PLGMA refers to sample printed a day prior to HaCaT seeding, and
HaCaT/HDF(7)-PLGMA refers to samples printed a week prior to HaCaT seeding.
Fluorescent images from immunohistochemical staining with antibodies against CK10 =
cytokeratin 10, and Ki67. Scale bars as indicated.

In this study, the human immortalized cell line HaCaT was used as a proxy model for
keratinocytes in human skin. Although primary cells are frequently used for 2D-3D in
vitro culture systems, HaCaT cell line has been successfully used to fabricate the
epidermal compartment of 3D skin model with typical epithelial morphology,
demonstrating to be reproducible and reliable.[105, 106, 135]
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Preliminary experiment was performed to study the influence of HDF on HaCaT
differentiation and stratification. Two groups were used on this experiment, HDF
printed one day prior to HaCaT seeding (HaCaT/HDF(1)-PLGMA) and HDF printed a
week prior to HaCaT seeding (HaCaT/HDF(7)-PLGMA). After a week of culture under
ALI conditions, the expression of keratinocytes differentiation marker, such as
cytokeratin 10 (CK10), and proliferation marker, Ki67, were assessed. Ki67 and CK10
markers were expressed in both HaCaT/HDF(1)-PLGMA and HaCaT/HDF(7)-PLGMA
constructs after culture for a week, however, HaCaT/HDF(7)-PLGMA showed better
structural organisation with significant change of nuclei shape in the most outer HaCaT
layer in comparison to HaCaT/HDF(1)-PLGMA (Figure 3.3). HDF printed a week prior
to HaCaT seeding (HaCaT/HDF-PLGMA) was then selected for the following
experiments.
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Figure 3.4 Assessment of HaCaT differentiation in 3D printed HDF-PLGMA cultured
in ALI for 2 weeks.
Fluorescent images from immunohistochemical staining with antibodies against CK10,
involucrin and collagen IV. Coll3 = collagen III, col4 = collagen IV, and inv =
involucrin. Scale bars as indicated.

The expression of cytokeratin 10 and involucrin was detected in the superficial HaCaT
layer of the HaCaT/HDF-PLGMA epidermal compartment after two weeks of culture
under ALI conditions (Figure 3.4). Expression of collagen III was observed in the
dermal compartment of HaCaT/HDF-PLGMA samples cultured under ALI conditions
for two weeks. The separation of epidermal layer from dermal layer observed in the
zoomed-out staining images (Figure 3.4) is due to the cryosectioning method which
disintegrated these structures during sectioning process.
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Figure 3.5 Assessment of HaCaT differentiation in 3D printed HDF-PLGMA cultured
in ALI for three weeks.
Fluorescent images from immunohistochemical staining with antibodies against
cytokeratin CK10, involucrin and collagen IV. Scale bars as indicated.

The expression of cytokeratin 10 and involucrin was strongly observed on HaCaT/HDFPLGMA samples cultured for three weeks under ALI conditions, as shown in Figure
3.5. Low expression of collagen IV (Figure 3.4 and 3.5) was also observed in the
epidermal component of the HaCaT/HDF-PLGMA samples. The staining of collagen
IV in the epidermal compartment, instead of the basement membrane could indicate that
collagen IV just started to be secreted by keratinocytes, and eventually would be
accumulated on the cell surface to form junction structures to anchor the epidermis to
the dermis. Taken all together, the expression of involucrin, cytokeratin, collagen III
and collagen IV confirmed the capacity of HaCaT/HDF-PLGMA platform to promote
normal epithelial morphogenesis and differentiation of keratinocytes.
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Figure 3.6 Relative gene expression of KGF and MMP-1
after 2-3 weeks of culture from HaCaT/HDF-PLGMA and HaCaT/HDF-GelMA control
group.

Keratinocytes stimulate fibroblasts to synthesize and secrete growth factors including
keratinocyte growth factor (KGF), which plays a critical role in supporting epidermal
proliferation.[198, 199] Higher expression of metalloproteinases (MMPs) is also
observed in fibroblast under the influence of keratinocytes [200] Therefore, expression
of KGF-1, MMP-1 were quantified to confirm keratinocyte-fibroblasts interaction and
assess the PLGMA matrix effect on the expression of those markers in HaCaT/HDFPLGMA cultured for 2-3 weeks. Data was compared to HaCaT/HDF cultured in
GelMA control group. qPCR data indicates higher expression of KGF-1, MMP-1 by
cells cultured in PLGMA possibly because of the PL growth factors, yet difference
between groups was not statistically significant (p ≥ 0.05).
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Figure 3.7 Histological assessment of HaCaT differentiation in 3D printed HDFPLGMA.
Bright field images from Masson's trichrome staining showing epidermal compartment
(keratin stained in red), dermal compartment (collagen stained in blue), cell cytoplasm
stained in pink and cell nuclei in dark brown.

The histological analysis of HaCaT/HDF-PLGMA samples, cultured for up to four
weeks under ALI conditions, was performed using Masson's trichrome staining. This
three-colour staining protocol used in histology stains keratin in red, collagen in blue,
cell cytoplasm in light red or pink and cell nuclei in dark brown to black. Bright field
microscope images show stratification evolution of the epidermal compartment of
HaCaT/HDF-PLGMA samples from day-0 to day-28 of culture under ALI conditions.
At day-0, HaCaT/HDF-PLGMA epidermal compartment shown to be thin and only
HaCaT cytoplasm and cell nuclei was stained. Figure 3.7 confirms stratification of the
HaCaT/HDF-PLGMA epidermal compartment after 2-3 weeks of culture under ALI
conditions, HaCaT/HDF-PLGMA epidermal compartment showed stratification with
high deposition of keratin and obvious change in epidermal structure. Moreover,
HaCaT/HDF-PLGMA dermal compartment demonstrated a remarkably porous
collagen-rich matrix with staining of some fibroblasts. The matrix morphology shown
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after three weeks of culture, could be due to keratinocyte and fibroblast secretion of
multiple enzymes that were degrading the matrix, as well as morphology distortion due
to artifacts/ice crystals formed during slow freezing. Paraffin-embedded samples should
be investigated, and protocol should be optimized in order to confirm the histological
morphology of the HaCaT/HDF-PLGMA samples.

3.3.2

HDF-PLGMA influence on hNSC H9

Figure 3.8 Bright field macroscope images of H9/HDF-PLGMA (day-1).
(A) day-1 culture of H9/HDF(1)-PLGMA – H9 neurospheres seeded in HDF-PLGMA
(printed 1-day prior H9 seeding). (B) day-1 culture of H9/HDF(7)-PLGMA – H9
neurospheres seeded in HDF-PLGMA (printed 7-days prior H9 seeding). Scale bar as
indicated.

Two groups were assessed in this section to study the influence of HDF on hNSC H9
neurospheres behaviour. H9/HDF(1)-PLGMA - HDF-PLGMA printed one day prior to
hNSC H9 seeding, and H9/HDF(7)-PLGMA - HDF-PLGMA printed a week prior to
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hNSC H9 seeding, as it was hypothesised that culturing HDF for days before
introducing the hNSC H9 would allow HDF to secrete signalling molecules and ECM
components, and therefore, provide a better environment for hNSC H9 to thrive. Bright
field macroscope images shows day-1 after the H9 neurosphere were seeded in both
experimental groups: Figure 3.8A shows the H9/HDF(1)-PLGMA; and Figure 3.8B
shows the H9/HDF(7)-PLGMA. Figure 3.8 also highlight the structure of the 3D printed
HDF-laden lattice construct, with HDF homogenously distributed throughout the matrix
and hNSC H9 spheres seeded in between strands. hNSC H9 were cultured as freefloating proliferating neurospheres, which embody heterogeneous populations of neural
progenitor cells and neural stem cells.

The aggregation of stem cells into 3D environment is mediated by intrinsic cell–cell
interaction as well as cell–ECM interactions.[201] Migration of cell out of spheres is
often initiated by plating neurospheres in a treated substrate and enriched medium
containing growth factors.[202-204] This data suggests that at a day after seeding,
hNSC H9 were already well integrated with the matrix and cells started to migrate out
of the sphere in both experimental groups, but more evident on H9/HDF(7)-PLGMA
samples (Figure 3.8B), where interaction of migrating cells with HDF filopodia were
also observed.
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Figure 3.9 Immunohistochemistry images of general neuronal markers in H9 cultured
for a week in HDF-PLGMA.
(A) Expression of β-tubulin III and S100B in H9/HDF(1)-PLGMA - H9 neurospheres
seeded in HDF-PLGMA (printed 1-day prior to H9 seeding). (B) Expression of βtubulin III and S100B in H9/HDF(7)-PLGMA - H9 neurospheres seeded in HDFPLGMA (printed a week prior to H9 seeding) (C) Staining images of trk receptors in
sectioned samples. Scale bar as indicated.

Figure 3.9A shows neurons stained with β-tubulin III and S-100B antibodies in
sectioned and un-sectioned H9/HDF(1)-PLGMA samples after a week of culture. Figure
3.9B shows neurons stained with β-tubulin III and S-100B antibodies in sectioned and
un-sectioned H9/HDF(7)-PLGMA samples after a week of culture. Lastly, Figure 3.9C
shows the expression of trk receptors in sectioned samples after a week of culture. Both
experimental groups demonstrated to support extensive neurite outgrowth, which was
confirmed by β-tubulin III staining. β-Tubulin III staining (black/white) images taken
with Leica inverted axiovert microscope better represent the overall 3D neurite network
in comparison to z-stacked confocal images (coloured images). Images of samples
stained with β-tubulin III antibody taken with the inverted microscope were processed
with ImageJ software to measure the average length of neurite outgrowth from
neurospheres. The length of 15 neurites branches were measured, then average and
standard deviation was calculated. Although measurement of neurite outgrowth was not
very accurate, neurite outgrowth from H9/HDF(7)-PLGMA samples (1904μm ± 386)
demonstrated to be about 2 times longer than H9/HDF(1)-PLGMA (926μm ± 218). By
that, we can conclude that fibroblast cultured for a week prior to the H9 seeding
secreted certain growth factors and other ECM components that promoted faster neurite
outgrowth from hNSC H9 neurospheres.
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Low expression of S100B marker was also observed on hNSC H9 neurospheres
cultured in both experimental groups H9/HDF(1)-PLGMA and H9/HDF(7)-PLGMA.
Immunohistochemistry images indicates the expression of Trk-A, -B and -C were
stained in sectioned samples of both groups. H9/HDF(1)-PLGMA and H9/HDF(7)PLGMA samples showed expression of all 3 tropomyosin receptors. These data all
together confirm neuronal differentiation of hNSC H9 cultured for a week in both sets
of HDF-PLGMA/H9 samples. Since H9/HDF(7)-PLGMA shown to support higher βtubulin III expression, next experiments were performed using HDF-PLGMA printed a
week prior H9 seeding.

Figure 3.10 Expression of mature/general neuronal markers in H9 cultured for 3 weeks
in HDF-PLGMA.
Immunohistochemistry images of β-tubulin III, MAP2, BRN3A, Neurofilament-200 and
collagen I in H9/HDF-PLGMA– 21-days culture of H9 neurospheres seeded in HDFPLGMA (printed 7-day prior H9 seeding). Scale bar as indicated.
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After three weeks of culture of hNSC H9 spheres in 3D printed HDF-PLGMA samples,
mature neuronal markers such as BRN3A, MAP2 and Neurofilament 200 were
expressed successfully (Figure 3.10). Images of H9/HDF-PLGMA cultured for three
weeks were stained with β-tubulin III antibody and processed with ImageJ software to
measure the average length of neurite outgrowth from neurospheres. Neurite outgrowth
from H9/HDF-PLGMA samples (2912μm ± 436) after cultured for three weeks, about
1.5 times longer than the neurites measured after two weeks of culture. Although the
measurement is not precise, this information reinforces the hypothesis that strong cellmatrix interactions support neurite outgrowth. Combining these data, it can be
concluded that neurospheres were maturing well in the dermal 3D printed HDFPLGMA construct after three weeks of culture.

Table 3.2 Bioink composition
Bioink ID
A
Ai
B
Bi
C
Ci
D
Di

PL (v/v)
50%
50%
50%
50%
50%
50%
50%
50%

GelMA (v/v)
7.5%
7.5%
5%
5%
6.25%
6.25%
6.25%
6.25%

LAP (v/v)
0.03%
0.03%
0.06%
0.06%
0.025%
0.025%
0.045%
0.045%

LAM (µl/mL)
10
10
10
10

Preliminary experiments were carried to assess the cytocompatibility of hNSC H9 cells
encapsulated in different PLGMA ink formulations. hNSC H9 cells were encapsulated
into eight different ink formulations containing different GelMA and LAP
concentrations (Table 3.2). The impact of matrix stiffness on cell behaviour was
assessed by qualitative screening of neurospheres morphology from bright field
macroscope images. Laminin is commonly used in neural stem cells (NSCs)
monolayered culture to support cell attachment, proliferation, and differentiation. Here,
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laminin was added to the ink formulation to study its ability to improve cell-matrix
interaction.

Figure 3.11 H9 spheres encapsulated in different inks after 4 days of culture. Scale bar
as indicated.

Bright field macroscope images displayed the morphology of hNSC H9 neurospheres
encapsulated in 8 different ink formulations after four days of culture. Most samples
(Figure 3.11 A, B, C, D, Ai and Di) showed neurite outgrowth hNSC H9 neurospheres
after the fourth day of culture, indicating general good cytocompatibility with the ink
formulations. Interestingly, bioinks without laminin showed slightly better neurite
outgrowth compared to the formulations containing laminin. Blank sample, free-floating
aggregates, cultured in matrix-free culture media, showed no neurite outgrowth.
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Figure 3.12 Viability of H9 (spheres and single cells) encapsulated in different inks

CellTiter-Glo® 3D viability assay was performed to determine the number of viable
hNSC H9 cells in neurospheres and dissociated neurospheres after four days of culture.
This method is based on quantitation of the ATP, which is a marker for the presence of
metabolically active cells. 16 samples plus three controls and one blankwere used for
this assay. Dissociated neurospheres, or ‘single cell’, were produced by mechanically
breaking spheres. In vitro cellular viability was performed to confirm cytocompatibility
towards hNSC H9 cells (Figure 3.12). All other formulations, except C and Ci, showed
high viability of hNSC H9 neurospheres. Dissociated hNSC H9 spheres (single cells)
showed low viability in all bioink formulations due to poor cell survival after
mechanical stress generated during the dissociation process. This could be due to
embryonic stem cell (ESC)-derived human NSCs own nature, as stem cells are known
to be a sensitive cell line that can be easily disrupted by mechanical stress.[205] In
summary, bioink formulations supported neurite outgrowth from neurospheres. No
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significant difference among the bioink tested were noted; yet sample ‘D’ (Figure
3.11D) showed a more uniform neurite outgrowth distribution throughout the sphere.

3.4

Discussion

It is well known that the tissue microenvironment plays an important role in a cell’s
fate. Human dermal fibroblast-derived matrix has been reported to support formation of
an optimal microenvironment for keratinocyte culture by depositing and rearranging the
ECM, as well as secreting many cytokines and growth factors required for keratinocyte
attachment and growth.[206] In accordance to that, our data showed that longer period
of culture of HDF-PLGMA prior to HaCaT seeding allowed HDF to attach to the
matrix, and initiate secretion of signalling molecules and ECM components, which
demonstrated to influence the keratinocyte fate and organisation.

The crosstalk between keratinocytes and fibroblasts are well known to be critical for a
successful healing process, as keratinocytes stimulate fibroblasts phenotype change and
synthesis of growth factors, and fibroblast stimulate keratinocyte proliferation in a
double paracrine manner.[207] Therefore, dermal-epidermal skin substitutes containing
keratinocytes and fibroblasts incorporated into constructs have the potential to promote
the regeneration of dermal and epidermal layers as well as accelerate wound closure, [4]
as cultured cells secrete ECM components, cytokines and growth factors to the wound
bed, managing wound healing and reducing pain.[207]

In normal skin, expression of proliferation marker Ki67 is observed in the basal layer
and immediate suprabasal layers,[208] while cytokeratin is expressed in suprabasal and
superficial keratinocytes layers.[209] Cytokeratins are cytoskeleton proteins expressed
by keratinocytes during differentiation. Involucrin is considered an early marker of
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keratinocyte terminal differentiation[210] expressed in the upper layers of the skin and
indicates the signalling between keratinocytes and fibroblasts.[211] The predominant
collagen subtype on the skin dermis is collagen type I and III with small amounts of
type V and IV in the basement membrane. Collagen IV, along with laminin, plays an
important role in cell adhesion, migration, differentiation, and growth. It promotes
keratinocyte migration, which is essential for the re-epithelialization of cutaneous
wounds. The expression of collagen IV is stronger in the co-culture of keratinocytes and
fibroblasts than in the mono-culture of keratinocyte alone, as fibroblasts secrete TGF-β,
which induce the synthesis of collagen IV by keratinocytes.[211] Although more indepth assessment in vitro and in vivo are needed to prove the therapeutic efficacy of the
proposed HaCaT/HDF-PLGMA platform in supporting new tissue formation and
epithelial maturation. This proof-of-concept study demonstrated that co-culture of
keratinocytes and fibroblasts-PLGMA expressed key epidermal differentiation protein
markers of cytokeratin 10, Ki67 and involucrin, indicating successful epidermal
stratification. HaCaT keratinocytes were used in this study to fabricate the epidermal
compartment of 3D skin model for its reproducibility capability, however, for future in
vivo studies patient-derived primary cells will be preferred as a biologically relevant
option.
There are seven β-tubulin isotypes expressed in human tissue,[212] which participate in
the formation of microtubule network. β-tubulin III, class III member of the β-tubulin
family specifically localized to neurons, plays an important role in neural differentiation
and neurite outgrowth. Therefore, β-tubulin III antibodies has been widely used as a
neuron-specific biomarker in developmental neurobiology and stem cell research.[213]
S100B is a cytosolic calcium-binding protein that belongs to the S100 protein
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family[214] expressed in astrocytes, specific neuronal populations, Schwann cells, and
others.[215] hNSC H9 cells also reported to express low level of this glial marker.
Study revealed the expression levels of glial markers (~ 1 × 106) was about 50 times
lower compared to β-tubulin III (> 50 × 106).[216] Tropomyosin receptor kinase (TrkA,
TrkB, and TrkC) are a transmembrane receptors family with tyrosine kinase activity that
plays an important role in the development of the mammalian nervous system.[217] Trk
receptors are primarily expressed in neuronal lineage of the dorsal root ganglia (DRG).
TrkA is a nerve growth factor (NGF) receptor; TrkB is a brain-derived neurotrophic
factor (BDNF) receptor; TrkC is a neurotrophin-3 (NT-3) primary receptor.[218]

Neuronal differentiation is characterised by an increase in the expression of several
neuron-specific markers including β-tubulin

III, MAP2, neurofilaments and

doublecortin. [216] MAP2 is a neuron specific protein expressed in immature neural
stem cells and neuronal cells. Reports suggest that mice expressed MAP2 shortly after
that of βIII-Tubulin. which stabilises the microtubule network in the dendrites of postmitotic neurons. [219] Expression of homeodomain transcription factor ISLET1 and
BRN3A protein has also been reported to indicate differentiation of stem cell lineages
into a neurosensory-like lineage.[220] Moreover, the expression of a cytoplasmatic
marker, 200 kD Neurofilament (NF200), is associated with large diameter
mechanoreceptor and proprioceptor neurons.[221]

It has been demonstrated in the literature that platelet lysate support angiogenesis,
neurogenesis and neuroprotection of endogenous neural stem cells (eNSC).[222] HDF
secrete multiple signalling molecules, such as PDGF, IGF-1, TGF-β, VEGF, HGF,
keratinocyte growth factor (KGF), interleukin (IL-6 and -8), tumour necrosis factor α
(TN-α)[223] and ECM components[13] that could influence this process as well.
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Although more in-depth assessment in vitro and in vivo are needed to understand how
these cells interact and if this interaction would lead to re-innervation of the wounded
skin. The proof-of-concept study here presented demonstrated that co-culture of
neuronal spheres and fibroblatsts-PLGMA supported the formation of a 3D nerve
networks in vitro. Direct contact of fibrobasts and hNSC promoted neurite migration
and neuronal maturation.
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3.5

Conclusion

Herein, we have demonstrated that the HDF-PLGMA platform established in the
previous chapter supported HaCaT differentiation, as well as hNSC-H9 neurosphere
neurite outgrowth and neuronal differentiation. HaCaT/HDF-PLGMA expressed
involucrin, cytokeratin, collagen III and collagen IV after cultured for two weeks under
ALI conditions, confirming the capacity of the platform to promote normal epithelial
morphogenesis and differentiation of keratinocytes. Stratification of keratinocytes were
also demonstrated my histological analysis. H9/HDF-PLGMA expressed development
neuronal markers including MAP2, BRN3A, neurofilament-200, as well as general
marker β-tubulin III after three weeks of culture, demonstrating the platform support
hNSC-H9 neurosphere neurite outgrowth and neuronal differentiation. Although the coculture of HaCaT and hNSC-H9 neurosphere together in an HDF-PLGMA construct
could not be demonstrated, important findings and challenges that need to be considered
in order to progress with this research were reported. Further standardization of the
system and characterisation techniques are required in order to incorporate other
relevant cells to fabricate more complex structures. Future work will also involve in
vivo studies to assess the ability of this system to improve re-epithelisation and reinnervation.

132

3.6

References

[4] R.F. Pereira, C.C. Barrias, P.L. Granja, P.J. Bartolo, Advanced biofabrication
strategies for skin regeneration and repair, Nanomedicine (Lond) 8(4) (2013) 603-21.
[13] M. Xue, C.J. Jackson, Extracellular Matrix Reorganization During Wound Healing
and Its Impact on Abnormal Scarring, Adv Wound Care (New Rochelle) 4(3) (2015)
119-136.
[58] M. Albanna, K.W. Binder, S.V. Murphy, J. Kim, S.A. Qasem, W. Zhao, J. Tan,
I.B. El-Amin, D.D. Dice, J. Marco, J. Green, T. Xu, A. Skardal, J.H. Holmes, J.D.
Jackson, A. Atala, J.J. Yoo, In situ bioprinting of autologous skin cells accelerates
wound healing of extensive excisional full-thickness wounds, Scientific Reports 9(1)
(2019) 1-15.
[91] W.L. Ng, J.T.Z. Qi, W.Y. Yeong, M.W. Naing, Proof-of-concept: 3D bioprinting
of pigmented human skin constructs, Biofabrication 10(2) (2018) 025005.
[94] W. Lee, J.C. Debasitis, V.K. Lee, J.-H. Lee, K. Fischer, K. Edminster, J.-K. Park,
S.-S. Yoo, Multi-layered culture of human skin fibroblasts and keratinocytes through
three-dimensional freeform fabrication, Biomaterials 30(8) (2009) 1587-1595.
[95] V. Lee, G. Singh, J.P. Trasatti, C. Bjornsson, X. Xu, T.N. Tran, S.-S. Yoo, G. Dai,
P. Karande, Design and fabrication of human skin by three-dimensional bioprinting,
Tissue Engineering, Part C: Methods 20(6) (2014) 473-484.
[97] D. Min, W. Lee, I.H. Bae, T.R. Lee, P. Croce, S.S. Yoo, Bioprinting of biomimetic
skin containing melanocytes, Experimental Dermatology 27(5) (2018) 453-459.
[101] N. Cubo, M. Garcia, J.F. del Cañizo, D. Velasco, J.L. Jorcano, 3D bioprinting of
functional human skin: production and in vivo analysis, Biofabrication 9(1) (2016)
015006.
[105] C. Intini, L. Elviri, J. Cabral, S. Mros, C. Bergonzi, A. Bianchera, L. Flammini, P.
Govoni, E. Barocelli, R. Bettini, M. McConnell, 3D-printed chitosan-based scaffolds:
An in vitro study of human skin cell growth and an in-vivo wound healing evaluation in
experimental diabetes in rats, Carbohydrate Polymers 199 (2018) 593-602.
[106] Y. Shi, T.L. Xing, H.B. Zhang, R.X. Yin, S.M. Yang, J. Wei, W.J. Zhang,
Tyrosinase-doped bioink for 3D bioprinting of living skin constructs, Biomedical
Materials 13(3) (2018) 035008.
[107] P. Admane, A.C. Gupta, P. Jois, S. Roy, C.C. Lakshmanan, G. Kalsi, B.
133

Bandyopadhyay, S. Ghosh, Direct 3D bioprinted full-thickness skin constructs
recapitulate regulatory signaling pathways and physiology of human skin, Bioprinting
15 (2019) e00051.
[114] B.S. Kim, J.-S. Lee, G. Gao, D.-W. Cho, Direct 3D cell-printing of human skin
with functional transwell system, Biofabrication 9(2) (2017) 025034.
[115] B.S. Kim, G. Gao, J.Y. Kim, D.W. Cho, 3D cell printing of perfusable
vascularized human skin equivalent composed of epidermis, dermis, and hypodermis for
better structural recapitulation of native skin, Advanced Healthcare Materials 8(7)
(2019) 1801019.
[116] B.S. Kim, Y.W. Kwon, J.-S. Kong, G.T. Park, G. Gao, W. Han, M.-B. Kim, H.
Lee, J.H. Kim, D.-W. Cho, 3D cell printing of in vitro stabilized skin model and in vivo
pre-vascularized skin patch using tissue-specific extracellular matrix bioink: a step
towards advanced skin tissue engineering, Biomaterials 168 (2018) 38-53.
[117] K. Derr, J. Zou, K. Luo, M.J. Song, G.S. Sittampalam, C. Zhou, S. Michael, M.
Ferrer, P. Derr, Fully three-dimensional bioprinted skin equivalent constructs with
validated morphology and barrier function, Tissue Engineering, Part C: Methods 25(6)
(2019) 334-343.
[135] W. Wan, F. Cai, J. Huang, S. Chen, Q. Liao, A skin-inspired 3D bilayer scaffold
enhances granulation tissue formation and anti-infection for diabetic wound healing,
Journal of Materials Chemistry B 7(18) (2019) 2954-2961.
[193] B. Laverdet, A. Danigo, D. Girard, L. Magy, C. Demiot, A. Desmoulière, Skin
innervation: important roles during normal and pathological cutaneous repair, Histol
Histopathol 30(8) (2015) 875-92.
[194] A. Sebastian, S.W. Volk, P. Halai, J. Colthurst, R. Paus, A. Bayat, Enhanced
Neurogenic Biomarker Expression and Reinnervation in Human Acute Skin Wounds
Treated by Electrical Stimulation, Journal of Investigative Dermatology 137(3) (2017)
737-747.
[195] S.G. Gürgen, O. Sayın, F. Cetin, A. Tuç Yücel, Transcutaneous electrical nerve
stimulation (TENS) accelerates cutaneous wound healing and inhibits pro-inflammatory
cytokines, Inflammation 37(3) (2014) 775-84.
[196] T. Weng, P. Wu, W. Zhang, Y. Zheng, Q. Li, R. Jin, H. Chen, C. You, S. Guo, C.
Han, X. Wang, Regeneration of skin appendages and nerves: current status and further
challenges, Journal of Translational Medicine 18(1) (2020) 53.
134

[197] Y.J. Choi, Y.J. Jun, D.Y. Kim, H.G. Yi, S.H. Chae, J. Kang, J. Lee, G. Gao, J.S.
Kong, J. Jang, W.K. Chung, J.W. Rhie, D.W. Cho, A 3D cell printed muscle construct
with tissue-derived bioink for the treatment of volumetric muscle loss, Biomaterials 206
(2019) 160-169.
[198] S. Werner, T. Krieg, H. Smola, Keratinocyte–Fibroblast Interactions in Wound
Healing, Journal of Investigative Dermatology 127(5) (2007) 998-1008.
[199] S.N. Menon, J.A. Flegg, S.W. McCue, R.C. Schugart, R.A. Dawson, D.L.S.
McElwain, Modelling the interaction of keratinocytes and fibroblasts during normal and
abnormal wound healing processes, Proceedings. Biological sciences 279(1741) (2012)
3329-3338.
[200] B. Russo, N.C. Brembilla, C. Chizzolini, Interplay Between Keratinocytes and
Fibroblasts: A Systematic Review Providing a New Angle for Understanding Skin
Fibrotic Disorders, Frontiers in immunology 11 (2020) 648-648.
[201] S. Sart, A.-C. Tsai, Y. Li, T. Ma, Three-dimensional aggregates of mesenchymal
stem cells: cellular mechanisms, biological properties, and applications, Tissue
engineering. Part B, Reviews 20(5) (2014) 365-380.
[202] J. Imitola, K. Raddassi, K.I. Park, F.J. Mueller, M. Nieto, Y.D. Teng, D. Frenkel,
J. Li, R.L. Sidman, C.A. Walsh, E.Y. Snyder, S.J. Khoury, Directed migration of neural
stem cells to sites of CNS injury by the stromal cell-derived factor 1 /CXC chemokine
receptor 4 pathway, Proceedings of the National Academy of Sciences 101(52) (2004)
18117-18122.
[203] M. Moors, J.E. Cline, J. Abel, E. Fritsche, ERK-dependent and -independent
pathways trigger human neural progenitor cell migration, Toxicol Appl Pharmacol
221(1) (2007) 57-67.
[204] H.J. Kim, M.R. Shaker, B. Cho, H.M. Cho, H. Kim, J.Y. Kim, W. Sun, Dynaminrelated protein 1 controls the migration and neuronal differentiation of subventricular
zone-derived neural progenitor cells, Scientific Reports 5(1) (2015) 15962.
[205] J. Tower, Stress and stem cells, Wiley interdisciplinary reviews. Developmental
biology 1(6) (2012) 789-802.
[206] C.-W. Wong, C.F. LeGrand, B.F. Kinnear, R.M. Sobota, R. Ramalingam, D.E.
Dye, M. Raghunath, E.B. Lane, D.R. Coombe, In Vitro Expansion of Keratinocytes on
Human Dermal Fibroblast-Derived Matrix Retains Their Stem-Like Characteristics,
Scientific Reports 9(1) (2019) 18561.
135

[207] H. Savoji, B. Godau, M.S. Hassani, M. Akbari, Skin Tissue Substitutes and
Biomaterial Risk Assessment and Testing, Frontiers in Bioengineering and
Biotechnology 6(86) (2018).
[208] G.K. Patel, C.H. Wilson, K.G. Harding, A.Y. Finlay, P.E. Bowden, Numerous
Keratinocyte Subtypes Involved in Wound Re-Epithelialization, Journal of Investigative
Dermatology 126(2) (2006) 497-502.
[209] G.N. Van Muijen, S.O. Warnaar, M. Ponec, Differentiation-related changes of
cytokeratin expression in cultured keratinocytes and in fetal, newborn, and adult
epidermis, Exp Cell Res 171(2) (1987) 331-45.
[210] H. Vala, T. Carvalho, C. Pinto, M.A. Pereira, J.R. Mesquita, C.P. M, L. Ferrer, D.
Fondevila, Immunohistochemical Studies of Cytokeratins and Differentiation Markers
in Bovine Ocular Squamous Cell Carcinoma, Vet Sci 7(2) (2020).
[211] S. Nayak, S. Dey, S.C. Kundu, Skin Equivalent Tissue-Engineered Construct: CoCultured Fibroblasts/ Keratinocytes on 3D Matrices of Sericin Hope Cocoons, PLoS
ONE 8(9) (2013) e74779.
[212] E.-M. Jouhilahti, S. Peltonen, J. Peltonen, Class III beta-tubulin is a component of
the mitotic spindle in multiple cell types, The journal of histochemistry and
cytochemistry : official journal of the Histochemistry Society 56(12) (2008) 1113-1119.
[213] M.K. Lee, J.B. Tuttle, L.I. Rebhun, D.W. Cleveland, A. Frankfurter, The
expression and posttranslational modification of a neuron-specific beta-tubulin isotype
during chick embryogenesis, Cell Motil Cytoskeleton 17(2) (1990) 118-32.
[214] D.M. Murray, Chapter 13 - Biomarkers in neonatal hypoxic–ischemic
encephalopathy—Review of the literature to date and future directions for research, in:
L.S. de Vries, H.C. Glass (Eds.), Handbook of Clinical Neurology, Elsevier2019, pp.
281-293.
[215] J. Kato, C.I. Svensson, Chapter Nine - Role of Extracellular Damage-Associated
Molecular Pattern Molecules (DAMPs) as Mediators of Persistent Pain, in: T.J. Price,
G. Dussor (Eds.), Progress in Molecular Biology and Translational Science, Academic
Press2015, pp. 251-279.
[216] L.E. Oikari, R.K. Okolicsanyi, A. Qin, C. Yu, L.R. Griffiths, L.M. Haupt, Cell
surface heparan sulfate proteoglycans as novel markers of human neural stem cell fate
determination, Stem Cell Research 16(1) (2016) 92-104.
[217] B. Stoleru, A.M. Popescu, D.E. Tache, O.M. Neamtu, G. Emami, L.G. Tataranu,
136

A.S. Buteica, A. Dricu, S.O. Purcaru, Tropomyosin-receptor-kinases signaling in the
nervous system, Maedica 8(1) (2013) 43-48.
[218] A.M. Fagan, H. Zhang, S. Landis, R.J. Smeyne, I. Silos-Santiago, M. Barbacid,
TrkA, but not TrkC, receptors are essential for survival of sympathetic neurons in vivo,
The Journal of neuroscience : the official journal of the Society for Neuroscience 16(19)
(1996) 6208-6218.
[219] A.R. Murphy, J.M. Haynes, A.L. Laslett, N.R. Cameron, C.M. O'Brien, Threedimensional differentiation of human pluripotent stem cell-derived neural precursor
cells using tailored porous polymer scaffolds, Acta Biomaterialia 101 (2020) 102-116.
[220] N. Gunewardene, N.V. Bergen, D. Crombie, K. Needham, M. Dottori, B.A.
Nayagam, Directing human induced pluripotent stem cells into a neurosensory lineage
for auditory neuron replacement, Biores Open Access 3(4) (2014) 162-75.
[221] A.J. Alshawaf, S. Viventi, W. Qiu, G. D’Abaco, B. Nayagam, M. Erlichster, G.
Chana, I. Everall, J. Ivanusic, E. Skafidas, M. Dottori, Phenotypic and Functional
Characterization of Peripheral Sensory Neurons derived from Human Embryonic Stem
Cells, Scientific Reports 8(1) (2018) 603.
[222] Y. Hayon, O. Dashevsky, E. Shai, D. Varon, R.R. Leker, Platelet lysates stimulate
angiogenesis, neurogenesis and neuroprotection after stroke, Thromb Haemost 110(2)
(2013) 323-30.
[223] J.N. Mansbridge, K. Liu, R.E. Pinney, R. Patch, A. Ratcliffe, G.K. Naughton,
Growth factors secreted by fibroblasts: role in healing diabetic foot ulcers, Diabetes
Obes Metab 1(5) (1999) 265-79.

137

4 Chapter

Electrofluidic control of bioactive molecule delivery into soft tissue
models based on gelatin methacryloyl hydrogels using threads and
surgical sutures
The work presented in this chapter was adapted from the manuscript published in the
Journal Scientific Reports 10, 7120 (2020). https://doi.org/10.1038/s41598-020-63785-z by
Cabot, J.M., Daikuara, L.Y., Yue, Z. et al. Electrofluidic control of bioactive molecule
delivery into soft tissue models based on gelatin methacryloyl hydrogels using threads and
surgical sutures. (The authors Cabot, J.M., Daikuara, L.Y. equally contributed to this
published work)
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Introduction

Thread and textiles have recently gained considerable attention as low-cost substrates
for microﬂuidics and biosensor applications, based upon their mechanical strength and
the ability to facilitate and direct fluid movement. Fluid flow in threads arise from
wicking processes as a result of capillary forces generated within the gaps between
directionally aligned fibres. This capillary action subsequently drives the fluid along the
thread, and it is directly related to the material hydrophilicity on the surface.[136] For
instance, the presence of waxes such as those composed of long fatty acid chains found
on some natural fibres like cotton as well as contamination on synthetic fibres such as
polyester have been observed to interfere with wicking in threads[142, 143] Threads
have been used in this way within a variety of applications, including bioanalysis,[137143] and embedded in a hydrogel as a network for chemotaxis studies[144] or
multilayer feeding of cell cultures.[145]

Hydrogels can be produced to simulate the characteristics of native extracellular
matrices and provide a 3D support for cellular growth and tissue formation.[224, 225]
The ability of hydrogels to mimic the mechanical properties of soft tissue has seen them
extensively applied in biomedical applications,[226] particularly presenting as an
attractive substrate for biomedical implants[227, 228] tissue engineering,[225, 229] and
as a therapeutic delivery platform.[230] Among the natural polymers, gelatin
methacryloyl (GelMA) presents several interesting advantages, as it is in fact denatured
collagen and is a photopolymerizable hydrogel.[231-235] The mechanical properties of
a variety of soft tissues, including neural tissue, vascularization, cartilage, bone, skin,
140

skeletal muscle, cardio, liver, and kidney can be reproduced through use of appropriate
GelMA concentrations and the photo-crosslinking conditions.[124, 235-238] Moreover,
GelMA’s mechanical properties and application can be further expended by
incorporating additional materials.[239] Here we use GelMA based hydrogels as tissue
models to demonstrate an effective way to control the delivery and spatial distribution
of biomolecules.

Threads can be readily integrated into the gel, and they provide for an easy and robust
way to transport liquid in or out of a gel. Direct application of biomolecules onto a
thread or yarn is trivial and enables dispatch at a targeted location.[138] Herein, we
demonstrated the use of electrofluidics – precise control and manipulation of fluids at
the microscale by the use of an external electric field – on threads/suture to deliver
biomolecules into and throughout a gel, via control of an applied electric field, to
provide a simple approach involving no moving parts or pumps.

This project was part of a collaboration between ARC Centre of Excellence for
Electromaterials Science (ACES) University of Tasmania (UTAS) and University of
Wollongong (UOW) nodes, where Dr Joan Marc Cabot and I, Luciana Yumiko
Daikuara, contributed equally to the published work. I was responsible for the selection
of sutures, synthesise / preparation of the hydrogel and the experimental work, while Dr
Joan Marc Cabot was responsible for the system design and data analysis. Despite being
peripherally related to the overall PhD theme; this system could be potentially
integrated to the PLGMA matrix by printing the 3D skin cells-PLGMA on top of the
suture for precise delivery of growth factors and cells to the sutured wound.

4.2

Experimental Section
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4.2.1

Materials and reagents

Key materials used in this chapter are introduced in detail as follow.

Materials

Source

Cat no

Gelatin (porcine skin, Type A, 300 Bloom)

Sigma-Aldrich

G2500

Methacrylic anhydride

Sigma-Aldrich

P5927

Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP)

Sigma-Aldrich

900889

Dexamethasone 21-phosphate disodium salt (DSP)

Sigma-Aldrich

D9184

Fluorescein

Sigma-Aldrich

F6377

Riboflavin

Sigma-Aldrich

F6750

Rhodamine B

Sigma-Aldrich

R6626

Fluorescein isothiocyanate - bovine serum albumin (FITC-BSA)

Sigma-Aldrich

Fluorescein isothiocyanate - dextran (FITC-dextran)

Sigma-Aldrich

Hydrogel

Biomolecules

General reagents
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES)

Sigma-Aldrich

H4034

Phosphate buffered saline (PBS)

Life Technologies

14190136

Tris(hydroxymethyl)aminomethane (TRIS)

Sigma-Aldrich

252859

Acetonitrile

Sigma-Aldrich

271004

Ammonium acetate

Ajax FineChem

631-61-8

Milli-Q water with a resistivity of 18.2 MΩ cm
Thread / Surgical suture
Acrylic (diameter (Ø) 671 ± 58 µm, 4 ply, Marvel Soft Baby)

Bella Baby

Polyester surgical suture (USP 4/0)

KeeboMed Inc

Lactomer surgical suture (USP 3/0 Polysorb)

Covidien

Poliglecaprone 25 surgical suture (USP 3/0 Monocryl)

Ethicon

Polypropylene surgical suture (USP 3/0 Prolene)

Ethicon

Nylon surgical suture (USP 3/0 Ethilon)

Ethicon

Silk surgical suture (USP 3/0)

Ethicon

Polyglactin 910 surgical suture (USP 3/0 Vicryl)

Ethicon

Polyamide surgical suture (USP 0 Supramid)

SMI AG

Polyglycolic acid surgical suture (USP 0 Surgicryl PGA)

SMI AG

4.2.2

Preparation of GelMA hydrogels
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GelMA hydrogels were prepared by dissolving various amounts of GelMA (2.5-7.5%)
in two buffer solutions, PBS (5.0%) and TRIS/HEPES (5 mM), respectively. For each
solution, LAP was then added to the solution with a final concentration of 0.06%,
loaded into a customized hydrogel chamber and crosslinked upon UV light (400 nm)
exposure for 45 seconds, unless specified otherwise. GelMA volume was kept constant
at 15 mm3 (2.5 × 2.5 × 2.4 mm, length × width × height).

4.2.3

Mechanical properties of GelMA hydrogels

The mechanical properties of hydrogels were measured by indentation (EZ-S
mechanical tester, Shimadzu) using a compression mode. Each sample was prepared by
casting a polymer solution (15l) in a 2.5×2.5×2.5 mm custom mold. A cylindrical flatended stainless-steel indenter (990 μm in diameter) was attached to a 10 N load cell and
programmed to apply force to the hydrogel surface at a controlled displacement rate of
0.5 mm/min. The Young’s modulus of the hydrogel was calculated through the slope of
the applied force against indentation depth (0-100 μm) plot. The radius of the indenter
tip was 0.495 mm. The slope of the linear fit was then used to calculate the hydrogel
modulus (E). Young’s modulus was calculated for 2 different GelMA concentration
(5.0, 7.5%) and 3 cross-linking times (30, 45, and 60 s). 5 replicates were carried for
each determination.

4.2.4

Nuclear Magnetic Resonance (NMR)
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NMR was performed to verify the degree of functionalization of gelatin methacryloyl
(GelMA). NMR spectra were acquired at 30 oC using a Bruker Avance III HD 400 MHz
NMR spectrometer (Bruker BioSpin Corp.), and the data were analyzed using Bruker
Topspin software 3.7.5. For NMR analysis, GelMA samples (10 mg/mL) and gelatin
samples (4 mg/mL) were prepared in deuterium oxide (Sigma-Aldrich, Australia). The
lysine peak (2.8–3.0 ppm) was used to confirm the methacrylation degree. The
phenylalanine peak (7.1–7.4 ppm) was chosen to normalize the intensity of the lysine
peak. The lysine peak shown in Figure 4.S1 confirmed a high methacrylation degree of
87 ± 5%, calculated according to the ratio of the relative peak integrations of the lysine
protons in GelMa and gelatin.

4.2.5

Platform and experiment setup

Figure 4.1 Schematic of the suture-GelMA hydrogel delivery platform.
(A) consisting of two buffer chambers with hydrogel chamber sitting in the middle, and
a suture/thread wetted with preferred buffer to connect both liquid and hydrogel.

144

Fluorophore (fluorescein) was loaded at 5 mm before the hydrogel chamber. Electric
field was applied between inlet and outlet chambers. (B) A simple circuit diagram
representing the contribution of each electrical component of the platform when electric
field is applied. (C) Sequence of images depicting the parts and delivery process of
fluorescein (a model compound) in GelMA at (i) 0.00, (ii) 2.30, (iii) 4.30 and (iv) 7.40
min. Images were picked from the top of the platform at 510 nm emission filter.
Conditions: 5% GelMA and 45s cross-linking (stiffness of 4.3 kPa), sample loading: 2
μL fluorescein drop at 1.0 μg/mL, current of 100 μA. 5 mM Tris/HEPES buffer was
used for both inlet/outlet chambers and GelMA. Scale bar is 2 mm. Data presented here
are based on 6 replicates.

As illustrated in Figure 4.1A, experiments were conducted in a suture-GelMA hydrogelbased device designed by Joan Marc Cabot. The platform consisted of two 3D printed
inlet and outlet chamber at each end filled with 500 μL of 5 mM Tris/HEPES, a 3D
printed hydrogel chamber sitting in the middle with 15 μL of 5% GelMA cross-linked
for 45 s, and a 3D printed base to allow good alignment and support of these features.
GelMA Inlet and outlet chambers had a tubular guide to introduce the electrode, ring to
tie in the thread, and a basin. The total length of the thread from the inlet to the outlet
chamber was 30 mm, with 2.5mm embedded into the hydrogel. The hydrogel chamber
was 2.5 × 2.5 × 2.5 mm (xyz), had two holes in each side allowing the thread to go in
and out of the hydrogel. Features were designed using SolidWorks CAD software
(SolidWorks Corp., Dassault Systemes). Designs were 3D printed using an Eden 260VS
(Stratasys) with VeroClear or VeroWhite build material, and SUP707 water soluble
support. SUP707 support material was removed by agitation in 2 % NaOH for 2 hours
using a benchtop orbital shaker, followed by 4-6 hours in water. Finally, printed parts
were rinsed with Milli-Q water. To interconnect the system, a plasma-treated acrylic or
surgical suture was placed at the front part of the inlet chamber, along the hydrogel
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chamber up to the outlet chamber. Prior to analysis, all threads and sutures were plasma
treated for 1 min at 18 W in 0.2 Torr using Harrick Plasma Cleaner PDC-32G (Harrick
Plasma) connected to a PlasmaFlo Gas Flow Mixer PDC-FMG. A power supply,
HVS448 High Voltage Sequencer 3000D-LC (LabSmith) in conjunction with a voltage
modulator were used to generate an electric field between the electrodes immersed in
the inlet and outlet reservoirs. The output of the sequencer (voltage, current and
conductivity) was controlled and measured by a computer through the Sequence
Software (Labsmith).

4.2.6

Bioactive molecule delivery in suture-GelMA hydrogel

Fluorescein velocities were measured at 3 GelMA concentrations (2.5, 5.0, 7.5%) and 6
crosslinking time (0, 10, 20, 30, 45 and 60 seconds). Fluorescein was prepared in the
same buffer solution as the GelMA hydrogel and reservoirs (5 mM Tris/HEPES). A
drop (2 μL) of fluorescein compound was placed in the acrylic thread (shown as ‘drug
load’ in Figure 4.1A). An electric field was applied at a constant current of 100 μA
unless specified otherwise. 5% GelMA with 45 s cross-linking and the same
electrofluidic conditions and buffer conditions were carried out for the flow delivery
control.

To test bioactive delivery, the same experiment was repeated using rhodamine B,
riboflavin, FITC-BSA, FITC-dextran. Resistance comparation was carried out using 4
different buffers (5 mM Tris/HEPES, 50 mM Tris/HEPES, 2.5 % PBS, and 5% PBS).
Drug delivery of fluorescein in several 9 suture threads were measured at 250 µA of
current, 5% PBS buffer and 5% GelMA with 45 s cross-linking. Results are presented as
the average of 6 replicates. Temperature was monitored using an infrared camera (Ex
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series with MSX, FLIR Systems) and kept at 25 ± 1ºC. A USB microscope AM4113TGFBW (Dino-Lite Premier, Clarkson) fitted with a blue light-emitting diode for
excitation and a 510 nm emission filter was used to take fluorescence images and videos
(resolution of 1.3M pixels and 30fps). ImageJ (National Institutes of Health) was used
to analyse the region of interest (ROI) and then monitor the mean fluorescence intensity
value of the ROI versus time. The data was acquired from the moment the fluorescent
compound band entered the hydrogel. This software was also used to determine the
band position at each time, and velocity was calculated using division of band
displacement by time. In all cases, position was referenced to the front part of the band.

A similar experiment was performed to study the delivery of dexamethasone 21phosphate disodium salt (DSP) using 5% GelMA with 45 s cross-linking and 5% PBS
as buffer. A drop (2 μL) of DSP (1.0 mg/mL) was placed on medical surgicryl PGA
suture, and an electric field was applied at a constant current of 250 µA. Buffered
solutions from the inlet and outlet chambers were collected from three experiments
performed at two different running times (1 and 2 hours). Triplicates of the same
experiment without electric field were carried out for the blank. Then the buffer solution
from the chambers were collected. DSP content in all samples collected were measured
by high pressure liquid chromatography (HPLC).

4.2.7

HPLC analysis of drug-released samples

An Agilent 1260 Infinity HPLC system equipped with an Atlantis T3 5 µm 4.6 × 250
mm C18 Column (Waters) was employed for the study. A gradient HPLC method was
used for the analysis of DSP using a UV detector at 242 nm. The mobile phase
comprised A (20 mM ammonium acetate) and B (acetonitrile) with a flow rate of 1
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mL/min. The initial mobile phase was maintained at 23% B for 5 min, and then changed
linearly to 100% B in 1 min (5-6 min), maintained at 100% B for 4 min (6-10 min), and
finally, reduced linearly to 23% B in 2 min (10-12 min) and maintained at 23% B for 4
min (12-16 min). The injection volume is 10 µL, and each sample was filtered through a
0.22 µm regenerated cellulose syringe filter (Phenomenex Australia Pty Ltd). DSP
concentration within the chambers were determined using the parameters obtained from
the calibration curve (70 - 1500 ppb).
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4.3
4.3.1

Results
Mechanical properties of soft biological tissues

Figure 4.2 Tailoring mechanical properties of gelatin methacryloyl (GelMA) hydrogels
to match soft tissues.
(A) Young’s modulus for the hydrogels prepared from 5.0 (black) and 7.5 % GelMA
(grey). Error bars are based on the standard deviation of 5 replicates. (B) Comparison of
Young’s modulus developed in this work (dashed box) with the soft biological tissues
(grey bars). Dashed box represents the region for 5.0-7.5% GelMA. The Young’s
modulus values obtained for the GelMA hydrogels were compared with the values
reported within the literature for 7 soft biological tissues[240, 241].

The mechanical properties of the GelMA hydrogel affect the diffusion and delivery of
bioactive species.[242] GelMA is often described as mechanically tunable.[232, 243,
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244] Changes in degree of modification and photo-crosslinking conditions cause
different rates and extent of reaction, thus altering the mechanical properties of
GelMA.[245] In this work, the Young’s modulus was determined for 2 GelMA
concentrations. Figure 4.2A shows a Young’s modulus of 2.1 ± 1.0, 4.3 ± 1.7, 5.7 ± 1.2
kPa for the 5.0% GelMA hydrogel photo-crosslinked for 30, 45 and 60s, respectively,
and 7.9 ± 2.7, 9.8 ± 3.2, 11.1 ± 3.7 kPa for the 7.5% GelMA hydrogel photo-crosslinked
for 30, 45 and 60s, respectively. As seen in Figure 4.2B, values obtained matched those
of several soft tissues, particularly normal skin, liver and kidney. The use of lower
concentration GelMA (5%) provides gels that more closely mimic softer tissues such as
spinal cord, grey matter or muscle, with the highest concentration gels (7.5%) being
closer to cornea anterior, artery and vein.

4.3.2

Biomolecule delivery in GelMA hydrogels

4.3.2.1 Transport process

To achieve an effective flow and controlled biomolecule migration within hydrogels,
plasma-treated (hydrophilic) acrylic thread (diameter to 670 µm) was used. As
described in the Theory section available within the supplementary information,
biomolecule transport is directly proportional to the voltage. Nevertheless, the rise in
voltage must be compensated with a reduction in current, otherwise the power (product
of voltage and current) can generate Joule heating. Therefore, in order to reduce the
generated current and minimize Joule heating effects, a low conductivity buffer (5 mM
Tris/HEPES, 62.72 Ω m, pH 7.8, ionic strength 3.38 mM) was used. The temperature in
each set-up was monitored using an infrared camera and was shown to be 25 ± 1ºC.
This suggests the absence of any significant Joule effects during delivery.
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Figure 4.1C shows a schematic representation of the hydrogel chamber before solute
delivery (in this example fluorescein (FL), a negatively charged fluorophore), with FL
shown dropped directly onto the inlet acrylic thread. As soon as a current of 100 μA was
applied, the FL band migrated towards the anode (+) along the thread. When the band
entered the hydrogel, the velocity decreased as a result of the increased viscosity and the
dissipation of the field within the gel. FL then spreads radially from the thread, to form
a semi-sphere. Finally, as the band exits the gel the FL band becomes refocused onto
the outlet thread. This can be viewed as a Movie in the Supplementary Information,
which shows the delivery process. Less than 8 minutes was needed to transfer the FL
band along the thread through the hydrogel, and then exit on the thread. FL travelled
through the hydrogel at a constant velocity of 7.17 ± 0.50 μm s-1 (n = 6).

4.3.2.2 Delivery of bioactive species

A range of exposure times and GelMA concentrations were tested in order to evaluate
delivery with respect to gel stiffness. Shown in Figure 4.S3 are the data for FL velocity
within 2.5, 5.0, and 7.5 % GelMA, as a function of crosslinking time from 0, 10, 20, 30,
45 and 60 seconds. The velocities for GelMA 5% and 7.5% were compared with the
respective Young’s moduli and are shown in Figure 4.2A. To compare results, all
experiments were carried out using a 100 μA current. The velocity decreased linearly
with increasing the hydrogel stiffness as characterized by respective Young's modulus.
A velocity of 9.3 ± 0.4 μm s-1 at a Young’s modulus of 2.1 kPa was found, compared
with 11.2 ± 0.4 μm s-1 at zero crosslinking (Figure 4.3A).
In contrast, for a tougher hydrogel with Young’s modulus of 11.1 kPa, velocity was
much slower (3.6 ± 0.6 μm s-1). Increasing the concentration of a macromer, as is the
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case with GelMA, results in formation of more densely crosslinked polymer network
that is responsible for an increase in stiffness and therefore a reduction in ion
mobility[233, 235] – similar to the influence of agarose concentration in gel
electrophoresis, commonly known as sieving matrix. A resultant reduction in the ion
mobility produced sharper solute bands within the gel (Figure 4.3Bi-ii). An increase of
cross-linking caused an increase in stiffness within the hydrogel, hindering the delivery.
This phenomenon was observed within hydrogels of stiffness > 15 kPa.

Under the same conditions, a higher electric field provides faster solute delivery, up to a
point, when if the electric field is too high, the infusion of biomolecules into the
hydrogel cannot keep up with electrolyte movement and so accumulates at the threadgel interface. This could cause a localized increase in ion concentration and therefore
increase Joule heating and posterior hydrogel swelling. This was the case for a hydrogel
with stiffness of 11.1 kPa at a current of 150 μA. Normal delivery was observed for the
first two minutes, at which point the hydrogel began to swell, causing disruption of the
band (Figure 4.3Biii).
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Figure 4.3 Delivery in soft tissue models based on GelMA hydrogels.
In all cases 0.5 pg of sample was dropped on acrylic thread and 100 μA was applied for
electric field (unless specified otherwise). 5 mM Tris/HEPES buffer was used for both
inlet/outlet chambers and GelMA. Error bars are based on the standard deviation of 3
replicates. (A) Speed of fluorescein (FL, a model compound) as a function of the
stiffness (Young’s modulus). Trend line was y = - 0.63x + 10.52, R-squared = 0.9912.
Red dashed line represents the velocity at 0 crosslinking (11.2 ± 0.4 μm s -1). (B)
Representative pictures were taken for (i) 5% GelMA (45s cross-link, stiffness of 4.3
kPa) at 100 μA, (ii) 7.5% GelMA (30 s cross-link, 7.9 kPa) at 100 μA, and (iii) 7.5%
GelMA (60 s cross-link, 11.1 kPa) at 150 μA. Scale bar is 2.5 mm (C) Velocity of 5
different compounds and bioactive components: fluorescein (FL), rhodamine B
(RhDB), riboflavin (RFN), BSA, dextran) in a GelMA hydrogel with a stiffness of 4.3
kPa, conditions were the same as Figure 4.1. (D) Velocity as a function of the molecular
weight of the compound. Speed in hydrogel declines with molecular weight following a
trend of y = 4.02x-0.57, R-squared = 0.9879.
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Figure 4.3C-D show the velocities of several bioactive molecules within the GelMA
hydrogel, ranging from small metabolites to polysaccharides, to proteins, each with
different charge and functionality. While migration was relatively rapid along the
acrylic thread, each slowed rapidly as they entered the hydrogel. Small molecules such
as FL, Rhodamine B (RhDB), and Riboflavin (RFN) migrated faster, with velocities of
7.57 ± 0.55, 6.34 ± 0.20, 5.99 ± 0.40 μm s-1, respectively. Different migration directions
were observed depending on the solute charge. For instance, FL (-) migrated to the
anode, whereas the polarity needed to be switched for delivery of RhDB (+). Velocities
for larger molecules such as dextran (4kDa, 2.26 ± 0.55 μm s-1) and BSA (66.5 kDa,
0.33 ± 0.07 μm s-1) were substantially slower. This was caused by the hydrogel matrix,
where smaller molecules moved and migrated more rapidly, as they could move freely
through the polymer networks. Compared with small molecules, polysaccharides and
proteins migrated slowly, being BSA the slowest.

4.3.2.3 Flow delivery control

Figure 4.4 shows a plot for 4-step controlled delivery of a solute band into the GelMA
hydrogel: (I) band delivery from thread to the hydrogel (field on); (II) diffusion through
the gel (field off); (III) equilibration (field off); and (IV) removal (field on). The spatial
distribution of FL fluorescence was monitored versus time to determine the amount of
FL in the hydrogel for each step of the process.

This light was monitored using a microscope and images/videos were treated through
ImageJ. Light threshold was kept constant, and the FL distribution area was determined
by selecting the ROI (region of interest) area. In this case, 0.5 pg of FL loaded upon the
thread inlet segment was delivered as a band towards the hydrogel, when a current of 50
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μA was applied. In step (I), the radial distribution increased as the band entered in the
hydrogel at a constant velocity of 3.53 μm s-1. A slight increase in area was observed
due to band broadening of the solute zone. Once the band reached the middle of the gel,
the voltage was turned off (at 4.5 min). Then, as shown in step (II), FL diffused into the
3D hydrogel space – as area per unit time (with an average of 0.45 mm2/min), described
by Fick’s law. Approximately 11 min were needed to cover the entire 3D space of the
hydrogel with FL. Although 100% of the area was occupied, a concentration gradient
from the thread source to the gel walls was observed. Therefore, in step (III) and with
voltage still off, the system was left for an extra 9 minutes to equilibrate and achieve a
uniform concentration throughout the hydrogel.

Line-scanning mode of ImageJ was used to determine the light intensity vs. single pixelwide to recreate a plot of intensity profile along the delivery axis. Uniform
concentration throughout the hydrogel was set when peak height was < 10 a.u. (pixel
intensity), less than 3 times the standard deviation of noise level. No loss of FL out of
the hydrogel was observed during the 20 minutes without any applied electric field.
Finally, in step (IV), the electric field was again activated at 100 µA to remove the FL.
The removal rate was constant over time, taking 6.03 min to eliminate FL completely
from the platform. Removal velocity of the FL was measured to be 6.90 μm s-1. Note
that at 100 μA the speed of the FL was almost doubled compared with step (I) where the
current was only 50 μA.
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Figure 4.4 Controlled delivery via electric field into 3D GelMA hydrogel supports.
Distribution area of fluorescein (FL, a model compound) within hydrogel with stiffness
of 4.3 kPa as a function of time in 4 different steps. Buffer used w(I) band delivery, 50
μA, 4.5 min (●); (II) molecular diffusion, 11 min (▲); (III) equilibration, 9 min (♦); and
(IV) excess removal, 100 μA, 10 min (■). Solid line represents the current applied.
Representative images were taken at minutes 11.17 (insert A), 20.50 (insert B), and
27.00 (insert C). Trend line for excess removal was y = -0.9973x + 0.445, R-squared =
0.9887. Scale bars is 2.5 mm. Conditions were the same as for Figure 4.1.
4.3.3

Drug delivery using sutures

The performance of several commercially available sutures was investigated using
several electrolytes with increasing conductivity. Figure 4.5A shows the total resistance
(RT) for the electrolytes within acrylic thread with polyglicolic acid (PGA) suture using
4 different biological buffers with conductivities ranging from 0.0159 to 0.585 S/m. The
resistance is uniquely determined by the amount and conductivity of liquid that the
thread is holding. Reducing the suture diameter (PGA with low USP size) and using a
braided structure saw the total resistance being increased, allowing higher buffer
concentrations to be used, typically more compatible for cell viability. Using 5% PBS
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(0.585 S/m) at a constant current of 250 μA, voltage was reduced to only 5.42 V
between each extreme of a 15 mm3 hydrogel (2.5 mm long, 2.17 V/mm). This voltage
was considered acceptable although it could be lowered further by increasing the length
of the hydrogel chamber. Using the previous buffers (0.0159 S/m), a current of 250 μA
would increase too much the voltage in the hydrogel, causing Joule heating effects and
swelling.

Figure 4.5 Thread conductivity
(A) Electrolyte resistance versus conductivity comparison between acrylic thread
(diameter 670 µm) and surgicryl PGA (USP 0). Electrolytes were 5 mM Tris/HEPES
(0.0159 S/m), 50 mM Tris/HEPES (0.141 S/m), 2.5 % PBS (0.293 S/m), and 5% PBS
(0.585 S/m) (B) Representative pictures depicting the parts and delivery process of
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fluorescein (FL, a model compound) taken after 4 minutes of applied current for 4
sutures: i) Nylon (Ethilon, monofilament); ii) Polyamide (Supramid, twisted and
coated); iii) Polyglactin 910 (Vycril, braided and coated); iv) Polyglicolic acid
(Surgicryl, braided and coated). Stiffness of the hydrogel was 4.3 kPa. Sample was
loaded upon thread inlet segment with a 2 μL drop of a 1.0 μg/mL solution of FL. Scale
bar is 2.5 mm.

Nine commercially available sutures produced from different materials, structures,
sizes, and water absorption characteristics were tested (Table 4.1). From these materials,
polyester, polyglactin 910, glycolide/lactide copolymer, and polyglycolic acid created
adequate fluid connection between the electrodes and the hydrogel (Figure 4.5B). Initial
delivery speeds ranged from 2.3 to 3.4 μm s-1. However, the velocity decreased when
the compound fully entered the gel. As commented previously, using 5% PBS and 250
µA the voltage in the hydrogel was very low. For this reason, the measurement of the
velocity in GelMA was extremely challenging and it is not shown.

Table 4.1 Chemical composition, structure, absorbability, and size of sutures.
Drug delivery speed of FL was measured for first 5 minutes of delivery at 250 μA, 5%
PBS. Conditions were the same as for Figure 4.5. Standard deviation based on 3
experiments.
Name®

Composition

Properties

Absorbable

Size
(USP)

Delivery
(μm s-1)

Monocryl

Poliglecaprone 25

Monofilament

91 - 119days

3/0

No

Prolene

Polypropylene

Monofilament

No

3/0

No

Ethilon

Nylon

Monofilament

No

3/0

No

Supramid

Polyamide based

Twisted and coated

No

0

No

Silk

Silk

Braided

No

3/0

No

Polyester

Polyester

Braided

No

4/0

3.4 ± 0.4

Vicryl

Polyglactin 910

Braided and coated

56 - 70 days

3/0

3.0 ± 0.3

Polysorb

Glycolide/Lactide copolymer

Braided and coated

56 - 70 days

3/0

2.9 ± 0.3

Surgicryl

Polyglycolic acid

Braided and coated

60 - 90 days

0

2.3 ± 0.3
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To demonstrate a potential application for controlled localized delivery, the delivery of
an anti-inflammatory drug, dexamethasone 21-phosphate disodium salt (DSP), was
investigated. DSP is a prodrug of dexmathasone that is used to treat many different
inflammatory conditions including skin inflammatory diseases and wound treatment. To
monitor the amount of DSP delivered, buffer electrolyte from both inlet and outlet was
examined using an HPLC. With an applied current of 250 μA, DSP was moving slowly
enough to be diffused off the suture and spread within the 3D hydrogel space. After
applying the electric field for 1 hour, DSP was only observed in the outlet reservoir at
very low concentrations (0.096 ppm), indicating 97.6% was still in the hydrogel. When
the electric field was applied for 2 hours, the percentage remaining within the hydrogel
was reduced to 81.1% of the drug. Furthermore, no DSP was found in the inlet
reservoir, proving that 100% of DSP was directed to the desired location and remained
there for this period, which would be essential for its actuation in the target area. The
applied electric field may also cause compounds presenting within the hydrogel to
migrate toward their oppositely charged electrode. Thus, there is significant potential
here to simultaneously monitor metabolites or products arising from the delivery of a
bioactive agent. Moreover, this setup could also be used to study drug-cell interactions
since metabolites and biomolecules of potential interest can be removed at will from the
hydrogel for their analytical determination, leaving the surviving cells in place.
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4.4

Discussion

Electrofluidic dynamics depend mostly on the physicochemical properties of the thread,
the physical properties of the hydrogel, and the composition of the electrolyte/buffer
used.[138, 141] Thread resistance (referred to the buffer suspended in the thread)
changes with the thread diameter, length and wettability (material hydrophilicity),
whereas hydrogel electrical resistance depends on gel dimensions, structure of
crosslinked networks and water content (Figure 4.S2).[138]

Electrolyte composition is also important, as increases in concentration or conductivity
will lead to higher currents. The magnitude of the applied current and polarity determine
both speed and direction (migration) of the solutes upon the thread. If a bioactive
species is present, its velocity would increase with the magnitude of the current.[138]
Due to the change in cross-sectional area, the magnitude of the current density is higher
along the bare thread, whereas it is substantially lower and spatially distributed within
the hydrogel. Consequently, the bioactive velocity is reduced when it enters the
hydrogel.

Structurally, braided sutures presented better connectivity, as they exhibit greater flowthrough properties, arising from the open braided structure, thus allowing a continuous
and homogeneous distribution of the electrolyte. However, braided silk sutures, a
protein based natural suture from the species Bombyx mori, could not be used as these
commercial sutures are typically processed to remove the natural waxes and gums, and
coated with a special wax mixture that prevents electrolyte penetrating into the
filaments.[246] Overall, the sutures which showed acceptable delivery performance can
be applied in main medical indications (skin, gastro-intestinal, uterus, hernia,
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orthopaedics, ophthalmic procedures, oral cavity, and muscle). Detailed information on
indication and contra-indication from these sutures can be found in Table 4.S1 from the
supporting information.

As illustrated in Figure 4.1, the 3D printed platform enabling this study comprised of
several parts: two reservoirs containing buffer and electrodes into which each end of the
thread is immersed. The thread travels from one reservoir to the other through the gel.
When current is applied between the two buffer chambers, a heterogeneous electrical
system is created, as shown in Figure 4.1B. Neither sutures/threads nor hydrogels are
electrically conductive. Electrolyte serve as ionic conducting medium. When external
electric field was applied, the electrokinetic phenomenon of electrophoresis was
observed and ultimately caused the presence of a charged interface on the surface and
the consequent migration of molecules.

By controlling electric field and polarity, small molecules, drugs or growth factors can
be dispatched in a controlled manner throughout the gel. The advantages of this
approach are that the rate of delivery can be controlled and, by controlling field on /
field off times, spatial control over the displacement of the molecule is achieved.

For an effective targeted delivery, the drug should move quickly in the suture but
slowed down when it is diffused off the suture to the gel, so that the desired biological
effect can be produced. This would benefit several biological processes such as more
efficient passive diffusion to a cell membrane or increase drug absorption for those with
low permeable coefficients. To achieve that, modifications in electrolyte resistances
were carried out, thus minimizing the electric field applied in the hydrogel and therefore
the velocity (Equation 6S).
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4.5

Conclusion

Herein, a novel system to release bioactive molecules such as small molecules, drugs,
polysaccharides, or proteins in a controlled manner via an electric field into tissue-like
3D hydrogel supports was reported. Threads and commonly employed sutures were
successfully assembled in GelMA-based hydrogels to facilitate the introduction of
bioactive species, and to deliver them via controlled diffusion to fill a desired 3D space.
Targeted drug delivery currently covers all means of delivering a bioactive species to a
target region, point, or receptor within a biological system; and covers bulk targeted
delivery (to a region) and selective drug delivery (to a specific receptor point, cell type
or other target biomolecule/species). Surgical sutures and electric field were put
together to deliver bioactive species into tissue-like materials. This work could use
commonly employed sutures as the delivery conduit to deliver anti-inflammatory drugs
for treatment of skin inflammatory diseases and wound infection. In addition, these
early assemblies demonstrate the possibility of using such scaffolds for applications in
bio-sensing and drug screening.
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Supplementary information
Theory

Electric field intensity, E (V/m), in a heterogenous system formed by a connection of different crosssectional parts (2 equal length thread/surgical suture and 1 hydrogel) is described by the following
relationship:

𝐸=

𝑉
𝑉𝑇
𝑉𝑇
=
=
𝐿 𝐿 + 𝐿𝐺𝑒𝑙 𝐿 + 𝐿𝐺𝑒𝑙
𝑡ℎ𝑑
𝑡ℎ𝑑
2
𝜒2
𝐴
( 𝐺𝑒𝑙2 )
𝜋𝑟

(1𝑆)

where 𝑉𝑇 is the voltage applied (V), 𝐿𝑡ℎ𝑑 and 𝐿𝐺𝑒𝑙 are the length of the individual parts of the thread and
GelMA hydrogel (m), 𝜒 is the ratio of the internal cross-sections of the parts, 𝐴𝐺𝑒𝑙 is the cross-section
area of the hydrogel (m2), and r the radius of the thread (m). Therefore, voltage in GelMA hydrogel (𝑉𝐺𝑒𝑙 )
and thread (𝑉𝑡ℎ𝑑 ) can be calculated by:
𝑉𝑡ℎ𝑑 = 𝐼𝑅𝑡ℎ𝑑 = 𝐼

𝐿𝑡ℎ𝑑 𝜌𝑡ℎ𝑑
= 𝐸𝐿𝑡ℎ𝑟𝑒𝑎𝑑
𝜋𝑟 2

(Eq. 2S)

𝑉𝑡ℎ𝑑 = 𝐼𝑅𝐺𝑒𝑙 = 𝐼

𝐿𝐺𝑒𝑙 𝜌𝐺𝑒𝑙
= 𝐸𝐿𝐺𝑒𝑙
𝐴𝐺𝑒𝑙

(Eq. 3S)

where I is the current intensity (A), 𝑅𝑡ℎ𝑑 is the resistance of the thread (Ω), 𝑅𝐺𝑒𝑙 the resistance of the gel
(Ω), and 𝜌𝑡ℎ𝑑 and 𝜌𝐺𝑒𝑙 are the respective resistivities of the thread and the gel (Ω cm). Knowing I,
voltage, and dimension of the thread and gel, 𝜌𝑡ℎ𝑑 and 𝜌𝐺𝑒𝑙 can be calculated using a modified equation
from 2S and 3S.
The change in resistance (f) can be calculated by:
𝐿𝑡ℎ𝑑 𝜌𝑡ℎ𝑑
𝑅𝑡ℎ𝑑
2
𝑓=
= 𝜋𝑟
𝐿𝐺𝑒𝑙 𝜌𝐺𝑒𝑙
𝑅𝐺𝑒𝑙
𝐴𝐺𝑒𝑙

(Eq. 4S)

Supposing that 𝜌𝑡ℎ𝑑 = 𝜌𝐺𝑒𝑙 , when a hydrogel of 2.5×2.5×2.4 mm (xyz; 15 μL) and a thread of radius 335
µm are used, the resistance within the hydrogel is 17-times lower. Whereas, if the thread radius is reduced
to 100 µm, hydrogel resistance becomes 190-times lower.
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Velocity of the band (𝑣̅ , m s-1) can be calculated as a function of the effective length (𝐿𝑒𝑓 , m) and time, or
the apparent mobility (𝜇̅ , m2V-1s-1), from the following:
𝑣̅ =

𝐿𝑒𝑓
= 𝜇̅ 𝐸
𝑡

(Eq. 5S)

Since the flow of the bulk solution is 0, 𝜇̅ equals the electrophoretic mobility (𝜇𝑒 ) and therefore this
equation can be rewritten as:
𝑣̅ = 𝜇𝑒 𝐸 =

𝑞𝐸
𝑞𝑉
=
6𝜋𝜂𝑟 6𝜋𝜂𝑟(𝐿𝑡ℎ𝑑 + 𝐿𝐺𝑒𝑙 )

(Eq. 6S)

where q and r are the charge of the respective ion charge and radius of the molecule, and 𝜂 the viscosity
(Pa·s) of the solution.

Figure 4.S 1 NMR spectra of gelatin and GelMA.
The red band is the lysine peak (2.8–3.0 ppm) used to quantify the degree of
methacrylation. In each spectrum, the integration of the lysine peak is normalised by
that of the phenylalanine peak (7.1–7.4 ppm, blue band).
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Figure 4.S 2 Schematic diagram depicting each of the electrodynamic considerations for
the thread – hydrogel system.

Figure 4.S 3 Speed of FL in the hydrogel
prepared from 2.5, 5.0, or 7.5 % of GelMA as a function of the crosslinking time. The
velocity clearly decreased with increasing GelMA concentration and photo-crosslinking
time. At low cross-linking times (≤~20 s), where the hydrogels were softer, velocities
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were much faster, close to that prior to the photocrosslinking (velocity of 11.17 μm s-1).
Conditions: 0.5 pg of sample was dropped on acrylic and 100 μA was applied for
electric field. Error bars are based on the standard deviation of 3 replicates.

Table 4.S 1 Compilation of indication/contra-indication from sutures studied in this
work.
Name

Monocryl

Composition

Poliglecaprone
25

Brand

Indication

Contra-indication

Ethicon

General soft tissue approximation
and/or ligation; subcuticular skin
closure

Cardiovascular or neurological
tissues, microsurgery or
ophthalmic surgery; where
extended approximation of tissue
under stress is required.

Prolene

Polypropylene

Ethicon

Ethilon

Nylon

Ethicon

Supramid

Polyamide

SMI

Silk

Silk

Ethicon

General soft tissue approximation
and/or ligation; cardiovascular,
ophthalmic, and neurological
procedures.
General soft tissue approximation
and/or ligation; cardiovascular,
ophthalmic, and neurological
procedures.
General soft tissue approximation
and/or ligation; skin closure.
General soft tissue approximation
and/or ligation; cardiovascular,
ophthalmic, and neurological
procedures.

Vicryl

Polyglactin 910

Ethicon

General soft tissue approximation
and/or ligation; ophthalmic
procedures.

Polysorb

Glycolide/lactid
e copolymer

Covidie
n

General soft tissue approximation
and/or ligation; ophthalmic
procedures.

Surgicryl

Polyester

Polyglycolic
acid

SMI

Polyester

Keebom
ed

General soft tissue approximation
and/or ligation; general surgery,
skin closure, gastrointestinal
surgery, gynaecology, obstetrics,
plastic surgery, urology,
ophthalmic surgery, orthopaedics.
General soft tissue approximation
and/or ligation; cardiovascular,
ophthalmic, and neurological
procedures.

166

Where extended approximation
of tissue is required.

Where permanent retention of
tensile strength is required.
Where extended approximation
of tissue is required .
Where permanent retention of
tensile strength is required.
Cardiovascular and neurological
tissues; where extended
approximation of tissue is
required.
Cardiovascular and neurological
tissues; where extended
approximation of tissue is
required.
Cardiovascular and neurological
tissues; where extended
approximation of tissue is
required.
Only veterinary use in the USA /
can be used in human or
veterinary procedures in other
countries.
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5.1

Conclusion

In the last decade, the advent of 3D printing and electrofluidic devices for tissue
engineering and regenerative medicine has engendered great interest for those involved
in skin repair and regeneration. 3D bioprinting allows spatial distribution of skin cells
into predefined custom-made structures to produce living skin mimics on the bench for
grafting. Electrofluidic technology, on the other hand, can be applied for fine controlled
delivery of bioactive molecules/drugs.

Therefore, the work presented in this thesis focused to meet challenges of traditional
approaches by describing for the first time, two innovative delivery system platforms
which could be potentially integrated or used separated in wound management.

Chapter 1 presents a general overview of the skin physiology, skin cells and extra
cellular components, stages of the wound healing process, compelling needs for
advance wound healing products, and emerging technologies to solve current gaps in
the clinic including bioprinting and electrofluidic approach. This chapter formed the
basis of a first author review recently submitted to the journal Advanced Functional
Materials entitled ‘Bioprinting for complex skin constructs fabrication’ 2021.

In chapter 2, studies aimed at establishing a foundation towards the development of a
more complex skin equivalent with complete functional performance were presented.
The results based on formulating a bioink containing PL and GelMA bioink (PLGMA),
which would work as a scaffold for encapsulation of skin cells and delivery of growth
factors while also mimicking key characteristics of native skin were presented. This
bioink was then used for the biofabrication of the PLGMA dermal-like structure and
this structure was used for initial in vitro characterisation. The results showed great
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promise in several aspects of skin tissue engineering, including high cytocompatibility
towards HDF, as well as promoting cell attachment and proliferation. Further benefits of
this system include increased synthesis and deposition of ECM molecules. This work
constitutes the major part of a first author paper that appears in the journal Acta
Biomaterialia 2021.[109]

In chapter 3, the fabrication of a more complex skin equivalent structure was proposed
by developing an innervated double layer skin-like structure based on the platform
HDF-PLGMA established on chapter 3. Although this study had to be interrupted
because of the coronavirus pandemic and the integration of the bilayer skin construct
with the innervated component could not be performed, initial studies demonstrated that
the PLGMA platform supported good cell-matrix interaction and provided optimal
microenvironment for differentiation of keratinocytes and hNSC-H9 neurospheres when
it was co-cultured with printed fibroblasts. In a proof-of-concept study, co-culture of
keratinocytes and fibroblasts in a 3D printed PLGMA construct reported very distinct
morphology in each layer (dermal and epidermal layer) in histological analysis. HDFPLGMA construct also demonstrated to support neurite outgrowth and maturation of
hNSC-H9 neurospheres over the period of 2 weeks of culture.

Chapter 4 details a novel electrofluidic/suture (e-suture) approach for controlled
delivery, which could be potentially used to deliver anti-inflammatory drugs such as
dexamethasone 21-phosphate disodium salt (DSP) for treatment of skin inflammatory
diseases and wound infection. This system was designed for precise manipulation of
fluids on commonly employed surgical sutures to deliver biomolecules into and
throughout a soft tissue model based on gelatin methacryloyl (GelMA) hydrogel, via
control of an applied electric field. In a proof-of-concept study, the proposed system
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showed great potential in delivering bioactive molecules such as small molecules,
drugs, polysaccharides, or proteins in a controlled manner via an electric field into
tissue-like 3D hydrogel supports. The advantages afforded by this delivery system are:
1) delivery can be turned on and off when needed; 2) during delivery the rate can be
controlled; 3) by alternating the field on/off, spatial control over the drug delivery is
possible; 4) the thread / suture chemistry can be modified to afford control over the
interaction and hence release of the bioactive species. This work was part of a
collaboration with Dr Joan Marc Cabot and Dr Brett Paull from University of Tasmania
and constitutes a significant component of a co-authored paper that appears in Scientific
Reports 2020.[247]
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5.2

Future directions

Future direction for the first 3D printed PLGMA platform involves 3D printing of the
dermal, epidermal and nerve component as well as incorporation of other relevant
cells/components, such as vascular components and other cutaneous appendages to
develop a fully functional skin equivalent. Future studies will also involve
demonstration of antimicrobial activity of PLGMA constructs against common airborne
bacteria, and in-depth studies in vivo (e.g., swelling and degradation studies, wound
healing histological analysis as well as evaluation of the construct adhesion strength to
the wound bed) to assess the therapeutic efficacy of the proposed PLGMA platform in
supporting skin tissue regeneration.

Figure 5.1 Schematic representation of the cell laden PLGMA 3D printed construct for
wound healing application.
Illustration shows the application of the proposed biosynthetic skin construct in the
clinic, implemented in a customizable and personalized approach. In this setting, cells
176

and PL would be harvested from the patient, expanded in the lab, encapsulated into the
PLGMA bioink, crosslinked, culture in the lab to allow matrix maturation by ECM
secretion, and implantation back to the patient, potentially promoting good
cosmetic/functional outcome.

Future directions for the e-suture includes redesign of the system, as current system is
not portable and would require long period of immobilization of an animal model for
the delivery of the bioactive molecules to be achieved. Therefore, further investigation
of the feasibility of the system will include the design of a portable system coupled with
a portable battery (which would provide the electric field), in vivo studies involving the
delivery of antimicrobial peptides to medium-sized animal model; and histological
analysis by hematoxylin and eosin staining for comparison of the wound healing of an
infected wound to an infected wound which received antimicrobial peptides through the
e-suture system.

PLGMA 3D skin construct and the e-suture systems described in this thesis could also
be integrated in the future by printing skin cell-PLGMA on top of the e-suture system to
create a skin equivalent electric-fluid device for better delivery control of relevant
molecules for wound management.
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Figure 5.2 Schematic representation of the e-suture system for would healing
application. Illustration of the portable device and its final application in the clinic. Redesigning the device would enable more flexibility to generate electric current for
controlled delivery of drugs to the sutured wound.

Although it is still at an early stage, bioprinting and electrofludic technology holds great
promise of producing living skin-mimicking tissues and delivery systems for medical
testing and clinical applications. It is envisaged those technologies will advance further
to alleviate the situation of an unmet need in skin transplantation. Yet, collaborative
work between academia, industry and regulations will be essential to move the field
forward. Advances in the regulatory frameworks and guidelines applicable to 3D
bioprinting and microfludics devices are needed to enable the translation of those
discoveries towards the use in a clinical setting. In order to facilitate development of
these technologies while protecting patients, it is important to ensure quality and safety
of materials and cells and establish specific standards for each stage of the printing
process with appropriate printing validation methods, and quality assessment.
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